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VENTRICULAR ARRHYTHMOGENESIS DURING ACUTE MYOCARDIAL ISCHEMIA 
The mechanism of early ventricula r f i b ri llation during acute 
myocardia l ischemia is undefined. A current hypothesis is t ha t the 
biochemical and metabolic sequelae of acute · myocardia l ischemia produce 
electrophy siological alterations in the ischemic my ocardium, viz. slow 
response action potentials . or depressed fas t response action potential s 
which i n turn facilitate the occurrence of reentry an d hence ventr i cular 
fibrillat i on . A fundamental b i ochemical change during ischemia i s 
extracellu lar potassium accumulation - such a n alterat ion decreases the 
resting membrane pote~tial of ischemic myocardia l ce lls and a lso 
inactivates the fast inward sodium current. I f t here i s mild o r moderate 
extracellular potassium accumulation then the fas t sodi um current may 
only be partial l y inactivated and generation o f a n action potentia l 
termed a depressed fast response - is dependent on reduced sodiurn inward 
current f l owi ng through the existing fas t channel s . I f t here is severe 
extracellula r potassium accumulat i on then t he fas t sodium c urrent may b e 
totally inactivated and generation of an action potentia l - termed a slow 
response - i s dependent on factors promoting the transsarcol ernrna l ca l cium 
inward current. A metabolic consequence of i schernia, v iz. enhanced 
adrenergic activity, promotes transsarcolernrna l ca l cium influx and has 
therefore been linked to the development of s l ow response potentials. 
The intracellular expression of enhanced adrenergic activity is 
considered to be mediated by cyclic AMP, the reputed second messenger of 
beta receptor stimulation. This proposal is based on the circumstantial 
association between myocardial accumulation of cyclic AMP. and the 
development of ventricular fibrillation and by the ability of 
(xii) 
cyclic AMP to induce slow responses in partially depolarized fibres. 
Slow responses and depressed fast responses are associated with slow 
rates of impulse propagation and have therefore been presumed to be 
responsible for the slow conduction and conduction block present in the 
ischemic myocardium. Slow conduction and conduction block predispose to 
the development of reentry which is currently considered to be the 
electrophysiological mechanism of early ventricular fibrillation. 
Electrophysiological mapping studies during acute myocardial ischemia 
link reentrant circuits to the development of ventricular fibrillation. 
The problem of ventricular arrhythmogenesis during acute myocardial 
ischemia is approached by an analysis of: (a) the biochemical and 
metabolic factors reputed to _produce alterations in the cardiac action 
potential; (b) the transsarcolemmal calcium current and the 
transsarcolemmal sodium current which underlie the development of slow 
responses and depressed fast responses respectively. 
Model 
The isolated Langendorff perfused rat heart was chosen as the model 
in which to study the problem of ventricular arrhythmogenesis in view of 
the following advantages: First, pharmacological agents can be added to 
the perfusion fluid and specific concentrations of such pharmacological 
agents can be attained in the myocardium. Secondly, alterations in the 
ionic milieu (eg. calcium ion) of the perfusion fluid is easily produced 
and the effect of such ionic alterations on ventricular arrhythmogenesis 
can be evaluated • Thirdly, the role of myocardial adrenergic receptor 
mediated influences on ventricular arrhythmogenesis can be determined. 
Fourthly, the role of metabolic and biochemical factors in ventricular 
arrhythmogenesis can be investigated. 
Methodology 
Ventricular fibrillation is induced by the train method of electrical 
(xiii) 
stimulation, electrical current ·being delivered by two stimulating 
electrodes across the surface of left ventricle during the T wave of the 
electrocardiogram i. e . during the vulnerable period. Ventricular 
fibrillation is defined as rapid, totally irregular ventricular rhythm 
for at least six beats and is accompanied by loss of left ventricular 
pressure. The lowest current required to induce ventricular fibrillation 
on two occassions is termed the ventricular fibrillation threshold. 
Acute regional myocardial ischemia of the left ventricle is produced 
by ligation of the left main coronary artery. The duration of acute 
myocardial ischemia is 15 minutes because the trough of the ventricular 
fibrillation threshold is reached within 10 to 15 min of coronary artery 
ligation. The heart rate and total coronary flow rate are recorded 
throughout the experiment. Biochemical and metabolic profiles are 
analyzed in freeze clamped hearts 15 mins after coronary artery ligation, 
i.e. at the nadir of the ventricular fibrillation threshold. 
Ventricular fibrillation induced by enhanced adrenergic stimulation 
The mechanism of catecholamine-induced ventricular fibrillation is 
analysed in view of the possible link between enhanced adrenergic 
activity and ventricular arrhythmogenesis during acute myocardial 
ischemia. Cyclic AMP, the reputed intracellular second messenger of 
beta-adrenergic stimulation, has been proposed to play a major role in 
the genesis of ventricular fibrillation induced by adrenergic 
stimulation. It has been further proposed that cyclic AMP may mediate 
its arrhythmogenic effect by promoting transsarcolenuna;t. calcium influx, 
thereby inducing calcium mediated electrophysiological alterations. 
If this hypothesis is correct then it might be anticipated that: 
(i) beta-adrenoceptor antagonist agents should prevent adrenaline-induced 
ventricular fibrillation by inhibiting the accumulation of cyclic AMP; 
(ii) calcium antagonist procedures should prevent adrenaline-induced 
(xiv) 
ventricular fibrillation by inhibiting the transsarcolemmal calcium 
inward current. 
Effect of beta adrenoceptor antagonist agents 
Adrenaline 5 X 
-8 -7 
10 M to 5 x 10 M produced a concentration 
dependent increase in the vulnerability to ventricular fibrillation in 
the non-ischemic heart; such an effect wa s not associated with a 
tempora l accumulation of myocardia l cyclic AMP. 
-7 
Adrenaline 5 x 10 M 
produced the greatest increase in both vulnerability to ventricular 
fibrillation and accumulation of cyclic AMP. 
- 5 
Beta-adrenoceptor antagonism with atenolol 5 x 10 M inhibited the 
adrenaline 5 X 
- 7 
10 M induced vulnerability to ventricular 
fibrillation. Dibutyryl cycl ic AMP, the analogue of cyclic AMP which 
penetrates the cell membrane more easily , enhanced the vulnerability to 
ventricula r fibrillation. Beta-adrenoceptor antagonism with atenolol 5 x 
-5 
10 M did not prevent the dibutyryl cyclic AMP induced ventricular 
fibrillation. 
The beta-adrenergic receptor appears to play a major role in the 
genesis of ventricular fibrillation induced by adrenergic stimulation in 
the non-ischemic heart. Cyclic AMP, the proposed intracellular second 
messenger of beta-receptor stimulation may not mediate the arrhythmogenic 
effect of enhanced adrenergic stimulation; 
simply reflect an epi -phenomenon. 
Effect of calcium antagonis t procedures 
Calcium channel antagonist agents, 
cyclic AMP accumulation may 
-7 
verapamil 1.5 x 10 M and 
nifedipine prevented the adrenaline 5 X 
-7 
10 M induced 
vulnerability to ventricular fibrillation. That calcium ions mediate the 
adrenaline-induced ventricular fibrillation is suggested by the following 
arguments: First, a reduction in the extracellular calcium ion 
concentration prevented the adrenaline-induced ventricular fibrillation. 
(xv) 
Secondly, 1 (-) verapamil, the isomer of veraparnil which inhibited the 
slow calcium inward current without altering the fast sodium inward 
current antagonized the catecholamine-induced ventricular fibrillation. 




adrenoceptors (Motulsky et al, 1983), and is therefore a 'pure 
calcium antagonist', protected against adrenaline-induced ventricular 
fibrillation. Fourthly, protection was not due to preservation of high 
energy phosphate content in the myocardium. Fifthly, a clear 
dissociation could be shown between effects on coronary flow rate and on 
antiarrhythmic activity. 
These findings suggest that calcium ions mediate the 
adrenaline-induced .vulnerability to ventricular fibrillation. Calcium 
ions may act as intracellular second messenger in mediating the 
arrhythmogenic effect of catecholamine stimulation . 
Ventricular fibrillation induced by acute myocardia l ischemia 
The role of the transsarcolemmal calcium current and the 
transsarcolemma l sodium current is investigated in the genesis of 
ventricular fibrillation during acute myocardia l ischemia. This approach 
is based on the hypothesis that slow response action potentials o= 
depressed fast response action potentials underlie the development of 
ventricular fibrillation during acute myocardial ischemia. 
Slow response action potential 
If calcium dependent slow responses underlie early ventricular 
fibrillation then: 
( 1) Beta-adrenoceptor antagonist agents which prevent accumulation of 
cyclic AMP should inhibit the cyclic AMP induced slow inward calcium 
current and thereby prevent slow responses and ventricular fibrillation. 
( 2) Alpha-adrenoceptor antagonist agents which decrease the 
(xvi) 
transsarcolemmal calcium inward current and possibly 
decrease 
intracellular calcium release should inhibit slow responses and thereby 
prevent ventricular fibrillation. 
( 3) Calcium channel antagonist agents, which decrease the 
transsarcolemmal calcium inward current, should inhibit the occurrence of 
slow responses and thereby prevent ventricular fibrillation. 
Depressed fast response action potential 
If depressed fast responses underlie early ventricular fibrillation 
then: 
(1) Fast channel blocking agents which decrease the transsarcolemmal 
sodium inward current should inhibit depressed fast responses and thereby 
prevent ventricular fibrillation. 
Effect of beta-adrenoceptor antagonist agents 
During acute myocardial ischemia, beta-adrenoceptor antagonist 
agents, atenolol 5 X and metoprolol 
-s 
10 M, in concentrations 
producing beta-receptor antagonism, are ineffective in preventing the 
enhanced vulnerability to ventricular fibrillation. In concentrations 
exceeding that required to produce beta-receptor antagonism, metoprolol 
l0-4M but not atenolol 
-4 
1 O M prevents the enhanced vulnerability to 
ventricular fibrillation during acute myocardial ischemia. Further 
investigation using dl-propranolol 5 X l0-
6
M and the d(+) isomer of 
propranolol 5 x l0-
6M show both agents to be equipotent in exhibiting 
ventricular antiarrhythmic activity. Protection against ventricular 
fibrillation could not be linked to reduction in heart rate, maintenance 
of coronary flow rate or preservation of metabolic status in the ischemic 
myocardium. The property common to dl-propranolol, d ( +) propranolol, 
high concentrations of metoprolol and lacking in atenolol is 'membrane 
stabilizing activity' . The beta-adrenoceptor, as judged by the effects 
of beta-antagonist agents, does not appear to play a role in the genesis 
(xvii) 
of ventricular fibrillation during acute myocardial ischemia. The 
ventricular antiarrhythmic activity of certain beta-antagonist agents 
appears to be due to a non-specific effect, viz. 'membrane stabilizing 
activity'. 
Role of cyclic AMP 
During acute myocardial ischemia, a temporal relationship exists 
between accumulation of cyclic AMP in the ischemic myocardium and the 
development of ventricular fibrillation. It has therefore been proposed 
that cyclic AMP, the reputed intracellular second messenger of 
beta-receptor stimulation, plays a major role in the genesis of 
ventricular fibrillation during ischemia. The accumulation of cyclic AMP 
in the ischemic myocardium is not inhibited by selective beta-receptor 
antagonism, i.e. metoprolol but rather by non-selective 
beta-receptor antagonism, i.e. metoprolol calcium channel 
antagonism, i.e. verapamil 1. 5 x l0-
7
M, and fast channel inhibition, 
i.e. lignocaine 
-s 
3 X 10 M. The reason for this puzzling and complex 
finding is unclear, but these findings indicate that generation of cyclic 
AMP in the ischemic myocardium may be dependent on factors other than 
beta-adrenoceptor stimulation. 
Does cyclic AMP play a role in the genesis of ventricular 
fibrillation during acute myocardial ischemia? Reduction in the cyclic 
AMP content in the ischemic myocardium was, in certain situations, 
circumstantially associated with protection against ventricular 
fibrillation, but, in other instances, unassociated with protection 
against ventricular fibrillation. Ventricular antiarrhythmic activity 
could also occur despite no reduction in cyclic AMP content in the 
ischemic myocardium. The evidence presented indicates that cyclic AMP 
may be linked to ventricular fibrillation, but only in certain 
situations. Cyclic AMP is not the only factor nor the final messenger of 
ventricular fibrillation. 
{xviii) 
Effect of alpha adrenoceptor antagonist agents 
Prazosin an antagonist; yohimbine an 
alpha
2 
antagonist, and phentolamine l0-
5
M, an alpha1 
and alpha
2 
adrenoceptor antagonist agent, each completely prevented the enhanced 
vulnerability to ventricular fibrillation during acute regional 
myocardial ischemia in the absence or presence of adrenergic 
stimulation. Protection was not due to reduction in heart rate, 
maintenance of higher coronary flow rates, preservation of metabolic 
status in the ischemic myocardium or due to reduction in the cyclic AMP 





adrenergic receptor mediated influences play a role 
in the genesis of ventricular fibrillation during acute myocardial 




receptor mediated effect. 
First, the protective concentration of prazosin (10-SM) is 
,!, 
1000-fold higher than the dissociation constant of the myocardial 
alpha
1 
receptor, whilst the protective concentration of yohimbine 
{ l0-6M) is 100 and 1000-fold higher respectively than the initial and 
final dissociation constants of the myocardial alpha 2 
adrenoceptor. 
Secondly, the protective concentration of prazosin, an alpha1 
antagonist, approximates that of yohirnbine, an alpha 2 
antagonist. 




receptor antagonist agents is difficult to reconcile on the 
basis of a specific receptor mediated event because of the disparate 
effect of alpha1 a
nd alpha
2 
receptor mediated influences on calcium 
fluxes. Fourthly, endogenous myocardial catecholamine depletion · by 
reserpine pre-treatment did not prevent the enhanced vulnerability to 
ventricular fibrillation during acute myocardial ischemia. Fifthly, the 
concentration of phentolamine which protects against ventricular 
(xix) 
fibrillation also inhibits the fast sodium channel and prolongs the 
action potential duration. Finally, the concentration of prazosin which 
protects against ventricular fibrillation also prolongs the action 
potential duration. The evidence presented suggests that the ventricular 
antiarrhythmic effect is likely to be due to a non-specific effect, i.e. 
'membrane stabilizing activity' or prolongation of the action potential 
duration rather than due to specific alpha1 or 
alpha 2 receptor 
antagoni·sm. However, two important aspects to note are that the 




is not clearly defined as is the regulation of extracellular and 
intracellular calcium ion movement by myocardial alpha1 
and alpha 2 





adrenergic receptors cannot be excluded in the 
genesis of ventricular fibrillation during acute myocardial ischemia. 
Effect of calcium antagonist procedures 
During acute myocardial ischemia, 
verapamil 1.5 x l0-
7M, nifedipine 
calcium channel antagonist agents 
l0-6M and diltiazem 5 x l0-
6M 
attenuated the enhanced vulnerability to ventricular fibrillation in the 
absence and presence of adrenergic stimulation. 
Protection was associated with reduction in heart rate, preservation 
of high energy phosphate, reduction in tissue cyclic AMP content and 
maintenance of higher total coronary flow rates; however, each of these 
factors could not account for ventricular antiarrhythmic activity. 
Redistribution of coronary flow . from the non-ischemic to the ischemic 
myocardium, although unlikely, could not be excluded in the mechanism of 
protection. That the transsarcolemmal calcium inward current plays a 
role in the genesis of ventricular fibrillation is suggested by the 
following factors: First, reduction in extracellular calcium ion 
concentration from 2.5 mM to 1.0 mM partially prevented the enhanced 
(xx) 
vulnerability to ventricular fibrillation during the acute myocardial 
-7 
Secondly, 1(-) veraparnil 1.5 x 10 M, which inhibits the ischernia. 
transsarcolernrnal calcium inward current without alteration of the 
transsarcolernrnal sodium inward current, partially prevented the 
vulnerability to ventricular fibrillation. Thirdly, nifedipine, shown 
not to interact with ,either alpha1 
or alpha 2 
adrenergic receptors, 
attenuated the vulnerability to ventricular fibrillation. The common 
property shared by the above three procedures is inhibition of the 
transsarcolernrnal calcium inward current. These findings suggest that the 
transsarcolemmal calcium current plays a role in the genesis of 
ventricular fibrillation during acute myocardial ischernia. 
Effect of sodium channel antagonist procedures 
The fast channel blocking agent lignocaine 3 
-5 
x 10 M completely 
prevented the enhanced vulnerability to ventricular fibrillation during 
acute myocardial ischemia. Protection was not due to reduction in the 
heart rate, maintenance of higher coronary flow rates during acute 
myocardial ischemia or preservation of metabolic status in the ischemic 
myocardium. Lignocaine inhibits the fast sodium inward current but also 
produces an alteration in the time independent outward potassium current, 
such an action may be responsible for ventricular antiarrhythrnic 
activity. Further investigation was therefore undertaken with 
tetrodotoxin, a specific inhibitor of the voltage dependent sodium inward 
current. Tetrodotoxin 3 x l0-
6M completely prevented the enhanced 
vulnerability to ventricular . fibrillation during ischemia - this effect 
was not mediated by alteration of heart rate, maintenance of coronary · 
flow, preservation of metabolic status or reduction in myocardial cyclic 
adenosine monophosphate content. These findings suggest that the 
transsarcolemmal sodium current plays a major role in the genesis of 
ventricular fibrillation during acute myocardial ischemia. 
(xxi) 
Conclusions: 
Ventricular fibrillation induced by enhanced adrenergic stimulation in 
the non-ischemic heart 
1) Beta-adrenoceptor antagonist agents, i n concentrations producing 
beta-receptor anta~onism, prevent the adrenaline-induced vulnerability to 
ventricular fibrillation . The beta-adrenergic receptor is directly 
implicated in the genesis of ventricular fibrillation induced by enhanced 
adrenergic stimulation. Cyclic AMP, the proposed intracellular second 
messenger of beta-receptor stimulation, may not mediate the 
arrhythmogenic effect of enhanced adrenergic activity, but merely be an 
epi-phenomenon . 
2 ) Calcium antagonist procedures prevent t he adrenaline-induced 
vulnerability to ventricula r fibrillation. Calcium ions appear to act as 
the intracel l ula r second messenger i n mediat i ng t he arrhythmogenic effect 
of enhanced adrenergic stimulation. 
Ventricular fibr i llation induced by acute regiona l myocardia l ischemia 
1 ) Beta-adrenoceptor antagonist agents, in concentrations producing 
beta-receptor antagonism, are ineffective i n preventing the enhanced 
vul nerability t o ventricu la r fibr i llation. I n concentrations higher than 
that required t o produce beta-adrenoceptor antagonism, some but not all 
beta-antagonis t agents prevent the enhanced vulnerability to ventricular 
fibrillation. The beta-adrenergic receptor does not appear to play a 
role in the genesis of ventricular fibrillation during acute myocardial 
ischemia. The ventricular antiarrhythmic activity of some 
beta-adrenoceptor antagonist agents appears to be due to a non-specific 
effect, eg. 'membrane stabilizing activity'. 
2) The accumulation of cyclic AMP in the ischemic myocardium appears to 
be dependent on factors other than beta-receptor stimulation. Cyclic AMP 
(xxii) 
may be linked to ventricular fibrillation but only in certain 






adrenoceptor antagonist agents prevent the 
enhanced vulnerability to ventricular fibrillation. The ventricular 
antiarrhythrnic activity appears to be due to a non-specific effect, i.e. 
'membrane stabilizing activity' or prolongation of action potential 









can exclude a role for either the alpha1 
or 
ventricular arrhythrnogenesis, the anatomical 
distribution of myocardial alpha1 
and alpha 2 
adrenoceptors and their 
regulation of extracellular and intracellular calcium ion movement needs 
to be clearly defined. 
4) Calcium channel antagonist agents and a reduction in extracellular 
calcium concentration attenuated the enhanced vulnerability to 
ventricular fibrillation. The transsarcolemmal calcium current appears 
to play a role in the genesis of ventricular fibrillation. 
5) Fast channel blocking agents prevented the enhanced vulnerability to 
ventricular fibrillation. The transsarcolemmal sodium current appears to 
play a major role in the genesis of ventricular fibrillation. 
CHAPTER 1 
HISTORICAL REVIEW AND EVOLUTION OF HYPOTHESIS UNDERLYING 
VENTRICULAR ARRHYTHMOGENESIS 
1. HISTORICAL REVIEW 
[A] Characterization of ventricular arrhythmias 
1-1 
Ventricular arrhythmias following experimental coronary artery 
occlusion were first described in 1894 by Porter as "fibrillar 
contraction of the left ventricle" • The pattern of ventricular 
arrhythmias following experimental coronary artery occlusion was 
characterized in 1909 by Lewis as ventricular extrasystoles, ventricular 
tachycardia and ventricular fibrillation. The size of ischemic 
myocardium was shown by Garrey in 1914 to be of critical importance in 
the genesis of ventricular fibrillation. Garrey illustrated that by 
successively cutting fibrillating ventricles into smaller and smaller 
sections, he could arrive at a section which did not allow fibrillation 
to occur. Thus the concept that reentry plays a role in the genesis of 
ventricular fibrillation was "born". The occurrence of ventricular 
extrasystoles, ventricular tachycardia and ventricular fibrillation 
following coronary artery occlusion in man was documented in 1921 by 
Robinson and Hermann. 
[B] Sympathetic nervous stimulation and ventricular arrhythmogenesis 
Between 1928 and 1934, evidence was presented showing that the 
sympathetic nervous system played a role in the genesis of ventricular · 
arrhythmias in the normal heart and also during acute myocardial 
ischemia. Otto in 1927 and Hoff and Nahum in 1934 showed that 
1-2 
catecholamine stimulation evoked formation of ventricular extrasystoles, 
ventricular tachycardia and ventricular fibrillation in the normal heart, 
whilst MacEachern (1940) demonstrated that sympathetic neural denervation 
decreased the incidence of ventricular fibrillation following coronary 
artery occlusion. 
[C] Vulnerable period and ventricular arrhythmogenesis 
A major advance in our understanding of ventricular 
arrhythmogenesis was provided by the superb studies of Wiggers et al 
( 1940) and Wegria et al ( 1941). Wiggers showed the following: First, 
ventricular fibrillation could be induced by electrical stimuli applied 
to the heart during the last 40 to 60 msec of systole and the first 
20 msec of diastole. He defined this period which corresponds to the T 
wave of the electrocardiogram as the vulnerable period. Induced or 
spontaneous impulses applied during the vulnerable period could evoke 
ventricular fibrillation. Secondly, the development of acute myocardial 
ischemia was associated with an increase in the vulnerable period and an 
enhanced vulnerability to ventricular fibrillation. Thirdly, he proposed 
that spontaneous ventricular fibrillation could be explained by "release 
of two successive stimuli, the first inducing a premature contraction and 
the second inducing fibrillation because it falls on the vulnerable 
period". 
[D] Early and late phase of ischemic ventricular arrhythmias 
Harris and associates in their elegant studies in the 1940's and 
early 1950's illustrated two time-dependent phases of ischemic 
ventricular arrhythmias and proposed a biochemical basis for the genesis 
of ischemic ventricular fibrillation. (1) Harris et al (1943; 1950) 
noted that ventricular arrhythmias following coronary artery occlusion 
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occur in two phases: (a) an early or immediate phase within the first 
two hours with maximal incidence in the first 30 mins. These early 
ventricular arrhythmias frequently terminate in ventricular 
fibrillation. An intervening quiescent phase, 2-12 hours after coronary 
artery occlusion; (b) a late or delayed phase, 12 hours after coronary 
artery occlusion which results in ventricular premature beats but 
infrequently in ventricular fibrillation. Harris proposed that the 
electrophysiological mechanism underlying the two phases of ventricular 
arrhythmias may be different. ( 2) Harris and associates illustrated a 
temporal relationship between cellular potassium loss from the ischemic 
myocardium and occurrence of ischemic ventricular arrhythmias (1954) and 
also showed that infusion of potassium salts into local areas of the 
myocardium induced ventricular tachycardia and ventricular fibrillation 
(Harris et al, 1958). A biochemical 
arrhythmogenesis was therefore proposed viz. 
arrhythmogenic (Harris et al, 1958). 
basis for ventricular 
that potassium ions were 
It was suggested that ventricular extrasystoles were generated 
from automatic foci in the ischemic myocardial cells bordering on the 
infarction zone. Harris attributed the excitability of ischemic cells to 
+ 
diastolic injury potential due to K induced depolarization from 
ischemic cells. 
2. ULTRASTRUCTURAL, ELECTROPHYSIOLOGICAL AND BIOCHEMICAL ALTERATIONS 
DURING ACUTE MYOCARDIAL ISCHEMIA 
Over the past twenty years there has been delineation of the 
ultrastructural, electrophysiological and biochemical alterations in 
acute myocardial ischemia and correlation of these changes with the early 
and late phase ventricular arrhythmias. This thesis addresses the 
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mechanism of early ventricular arrhythmias during acute myocardial 
ischemia. First, I will review the ultrastructural, electrophysiological 
and biochemical alterations evident during acute myocardial ischemia in 
the early phase of ventricular arrhythmias; secondly, I will illustrate 
the proposed links between biochemical and electrophysiological 
alterations and early ventricular arrhythmias; thirdly, I will highlight 
the proposed electrophysiological mechanism of early ventricular 
arrhythmias and fourthly, I will define the approach undertaken in order 











currents in the 
ventricular arrhythmias during acute myocardial ischemia. 




Within minutes of the development of acute myocardial ischernia, 
ultrastructural alterations are evident in ventricular myocardial cells 
in the area of ischemia (Sobel, 1974; Jennings & Ganote, 1974). A 
temporal relationship exists between ultrastructural changes in ischemic 
ventricular myocardial cells, electrophysiological alterations and the 
occurrence of early ventricular arrhythmias (Wit & Bigger, 1975). It 
has, therefore, been proposed that the early ventricular arrhythmias may 
result from electrophysiological alterations in ultrastructurally 
abnormal ischemic ventricular myocardial cells (Wit & Bigger, 1975). 
[BJ Electrophysiological alterations 
The onset of acute myocardial ischemia is associated with the 
development of electrophysiological alterations in the ischernic 
myocardium which are evident within 30 minutes of acute coronary artery 
occlusion, i.e. during the early phase of ventricular arrhythmias. Such 
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electrophysiological alterations have been linked to the occurrence of 
early ventricular arrhythmias. 
(1 ) Resting membrane potentia l and phase 0 
A decrease in resting membrane potentia l occurs within 7-10 mins 
of coronary artery occlusion and may reach -65 to -60 mV (Wit & Bigger , 
1975; Dawna~ et al, 1977; Kleber e t a l , 1978 ) . The decrease in resti n g 
membrane potential ( depolarization of the ventr i cular myocardial cel l) 
results i n partial or complete inactivation of the fas t sodium channel 
(Weidermann, 1970 ; Cranefield et al, 1972 ) . The quest i o n whic h i s a s 
ye t unanswered is whethe r the upstroke (p hase 0) of the depressed 
+ 
ischemic t ransmembrane action potentia l i s dependent on reduced Na 
inf l ux t h r ough the existing f ast channels (i .e . depressed fas t response 
action pote ntials ) , o r whethe r the upstroke i s dependent o n ca l cium i o n s 
flowing t hrough the slow c hanne l ( ca l cium-depende nt slow responses ) . I n 
some studies the upstroke o f t he action potentia l show two components 
(Downa r e t a l, 1977 ; 
+ 
Russel l e t a l , 19 7 7 ) sugge s t ing t ha t both Na a nd 
2+ 
Ca i ons may be responsible fo r generatio n o f t h e upstroke o f t he 
depressed a c t i o n potential. Depressed fas t responses o r s l ow responses 
are each associated wi t h slow conductio n a nd c o nduc t i o n block, pre di spose 
t o reentry and each may t hereby induce vent r i cu l a r a r r hythmias 
(Cranefie ld, 1975; Wi t & Bigger , 19 75 ) . 
(2 ) Transmembrane action potentia l 
Wi t h i n 2 mi n o f coronary artery occlusion t here is a decrease i n 
both act i on potential amplitude and action potent i al duration (Downar et 
al, 1977; Kleber et al, 1978; Kardesh, 1977). The decrease in action 
potential duration is mainly due to shortening of the plateau phase 
(Downar et al, 1977; Kleber et al, 1978; Russell et al, 1977). 
Reduction in action potential duration predisposes to shortening of the 
relative and absolute refractory period and is thereby arrhythmogenic. 
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(3) Recovery of excitability of refractoriness 
The absolute refractory period (i.e. threshold for excitation by 
applied stimuli) appears to shorten 2 min after ischemia (Brooks, 1960; 
Han & Moe, 1964; Levites et al, 1976; Niami et al, 1977). This 
alteration may be linked to shortening of the action potential duration 
and is theoretically arrhythmogenic. 
During later ( 10 min after ischemia) or severe ischemia, the 
absolute refractory period appears to lengthen. This alteration appears 
to be due to development of post-repolarization refractoriness, i.e. the 
recovery of the ability of a cell to generate an upstroke of an action 
potential is delayed beyond completion of repolarization (El-Sheriff et 
al, 1974; Lazzara et al, 1975). 
Gettes and Reuter (1974) showed that in cells with reduced 
resting membrane potentials recovery from inactivation of fast and slow 
inward currents is markedly delayed. Hence if adjacent ischemic 
myocardial cells have reduced resting membrane potentials, albeit at 
different levels, the recovery of cellular excitability is delayed and 
different, i.e. a dispersion of refractoriness may exist between adjacent 
ischemic cells. 
Dispersion of refractoriness between ischemic cells or between 
ischemic and non-ischemic myocardial cells predispose to conduction block 
and hence reentry and is therefore arrhythmogenic. 
(4) Conduction 
A decrease in conduction velocity occurs such that fragmented 
electrical activity may persist in the ischemic myocardium for as long as 
315 msec after the impulse has entered the area from the adjacent 
non-ischemic myocardium (Boineau & Cox, 1973). In addition, there is 
delayed activation of the ischemic myocardium, especially epicardial 
activation relative to the endocardium and development of conduction 
block. 




The occurrence of slow conduction, conduction block and 
alteration in refractoriness in ischemic myocardial cells are conducive 
to the formation of reentrant circuits (Cranefield, 1975). It is 
considered that the ischemic action potential, be it a calcium dependent 
slow response or depressed fast response, is responsible for slow 
conduction, conduction block and hence reentry in the ischemic myocardium. 
Strong evidence for reentry has been the circumstantial 
association between ventricular arrhythmias (including ventricular 
tachycardia and ventricular fibrillation) and prolonged conduction delay 
in the ischemic myocardium ( Janse et al, 1980; 1981) • Moreover recent 
electrophysiological mapping experiments during acute myocardial ischemia 
indicate that macro-reentrant circuits play the major role in ventricular 
tachycardia, whereas micro-reentrant circuits are evident during 
ventricular fibrillation (Janse et al, 1981). Re-entry has, therefore, 
been proposed as the likely electrophysiological mechanism of early 
ventricular arrhythmias during acute myocardial ischemia. 
(2) Injury current 
An alternative hypothesis is that injury current flowing from 
ischemic to non-ischemic cells across the border zone may evoke 
ventricular arrhythmias by excitation of non-ischemic cells in the border 
zone or by generation of micro-reentrant circuits or triggered 
automaticity in the border zone (Katzung et al, 1975; Janse et al, 1981). 
In diastole, the resting membrane potential of ischemic cells is 
reduced such that the intracellular compartment is positive to the 
intracellular compartment of normal cells. Intracellular current flows 
from ischemic to non-ischemic cells thereby generating current source in 
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the extracellular space of normal cells. (During systole current flow is 
opposite). If there is slow conduction in the ischemic myocardium and an 
area of inexcitability exists, such as the border zone, then current flow 
from ischemic cells to non-ischemic cells may reach non-ischemic cells at 
a time that they have repolarized. Hence excitation of normal cells or 
generation of micro-reentrant circuits in the border zone may occur and 
produce ventricular arrhythmias. Alternatively, current flow may induce 
formation of afterdepolarizations in the border zone which in turn may 
evoke triggered automaticity and ventricular arrhythmias (Cranefield, 
1977). 
[DJ Biochemical and metabolic alterations 
The onset of acute myocardial ischemia is associated with the 
development of metabolic and biochemical alterations in the ischemic 
myocardium within 30 min of the onset of ischemia, i.e. during the early 
phase of ventricular arrhythmias. These metabolic and biochemical 
alterations have been linked to the development of slow response action 
potentials or depressed fast response action potentials, i.e. abnormal 
action potentials presumed to be responsible for the slow ·conduction and 
conduction block present in the ischemic myocardium and held to underlie 
the development of reentry. Reentry is the likely electrophysiological 
mechanism of early ventricular arrhythmias. A biochemical basis for 
ventricular arrhythmogenesis has therefore been proposed. 
I will first illustrate the biochemical and metabolic 
alterations evident during acute myocardial ischemia and then demonstrate 
their proposed link to electrophysiological alterations recorded in the 
ischemic myocardium. 
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(1) Energy depletion, lactate accumulation, metabolic and 
respiratory acidosis 
In the acutely ischemic myocardium there is total or partial 
cessation in the extracellular delivery of oxygen and substrate, i.e. 
glucose, free fatty acid or lactate (Opie, 1978). High energy phosphate 
depletion occurs within 2 min of the onset of ischemia due to inhibition 
of o
2 
dependent mitochondrial energy production. Anaerobic metabolism 
is stimulated in order to produce energy; consequently there occurs: 
( 1) cellular accumulation of the end product of anaerobic metabolism -
lactate; levels rise within 2 min with peak values evident 20 min after 
the onset of ischemia (Opie et al, 1973); (2) metabolic acidosis due to 
(a) proton formation generated during hydrolysis of ATP (Gevers, 1977), 
(b) poor tissue washout. A fall in pH occurs within 15 min of ischemia, 
pH 7. 4 to 5. 5 in the pig (Hirche, 1980) and 7. 4 to 6. 0 in the baboon 
(Bruyneel, 1972); (3) accumulation of pco2 
and the development of 
respiratory acidosis (Khuri et al, 1975). 
(2) Free fatty acid metabolism 
Due to o
2 
lack, there is cessation or reduction in myocardial 
mitochondrial metabolism of free fatty acids with accumulation of free 
fatty acids and their metabolites, i.e. acyl CoA and acyl carnitine. In 
addition the elevated levels of circulating catecholamines hydrolyse 
triglycerides in peripheral adipose tissue, initially increasing plasma 
free fatty acid levels and subsequently acyl CoA and acyl carnitine. The 
effect of accumulation of free fatty acids and metabolites, i.e. CoA and 
acyl carnitine are: (i) reduction in energy formation due to failure to 
metabolise free fatty acids as fuel (Opie, 1978); (ii) inhibition of 
+ + 2+ 
energy dependent enzyme systems, eg. Na /K ATPase, Ca ATPase; 
(iii) accumulation of lysophosphoglycerides ( Sobel et al, 1978) due to 
a.nd acidos;s 
high levels of acyl CoA and acyl carnitine{ inhibiting enzymes responsible 
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for degradation of lysophosphoglycerides. 
(3) 
+ + 2+ 
Na~ and Ca 
Energy depletion and accumulation 'of ly.$0 phos phog lyce-ndes 
in the ischemic myocardium each inhibit energy dependent processes, eg. 
+ + 
Na /K ATPase (Opie, 1979). This results + in intracellular Na 
+ + 
accumulation, cellular K loss and extracellular K accumulation. 
+ Extracellular K accumulation occurs after l min of ischemia, peak 
levels between 10 to 16 mM/1 are evident within 20 min of ischemia. 
There is also intracellular Ca 2+ accumulation due to (a) intracellular 
Na+ accumulation, (b) inhibition of Na+ /Ca 2+ exchanger and ( C) 
2+ 
inhibition of energy dependent Ca ATPase. 
(4) Catecholamines 
Acute myocardial ischemia is associated with elevation in the 
circulating levels of catecholamines {Jewitt et al, 1969); an increase 
is evident within 30 secs and peak levels occur 40 min after coronary 
artery occlusion (!Carlsberg et al, 1979). There is probably also local 
release of noradrenaline from the ischemic myocardium (Hirche, 1980), the 
level in the interneuronal cleft may reach 
coronary occlusion (Dietz et al, 1981). 
-s 
10 M within 60 min of 
Enhanced adrenergic activity results in stimulation of both the 
alpha and beta adrenergic receptors. 
[E] Arrhythmogenic potential of the biochemical and metabolic changes 
The development of acute myocardial ischemia is thus associated 
with accumulation of the following biochemical and metabolic factors in 
the ischemic myocardium during the early phase of ventricular arrhythmias: 
( l) 
+ extracellular K ( 2) noradrenaline ( 3) cyclic AMP ( 4) free fatty 
acid and activated long chain metabolites ( 5) lysophosphoglycerides ( 6) 
metabolic acidosis ( 7) respiratory acidosis (8) lactate. The 
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arrhythmogenic potential of these metabolic and biochemical alterations 
is now described. 
(1) Potassium 
The development of acute myocardial ischemia is associated with 
+ 
cellular potassium loss and extracellular K accumulation (Thomas et 
al, 1970). Harris initially showed a temporal relationship between 
+ 
cellular K loss from the ischemic myocardium and occurrence of 
ventricular arrhythmias (Harris et al, 1943). Subsequently several 
+ 
workers found that infusion of K into the circulation resulted in 
ventricular arrhythmias and ventricular fibrillation. Potassium ions 
have therefore been implicated in ventricular arrhythmogenesis. 
Arrhythmogenic potential 
Extracellular K+ accumulation decreases the resting membrane 
potential and thereby .inactivates either partially or completely the fast 
sodium channel and predisposes to the development of depressed fast 
response action potentials or slow response action potentials, i.e. 
action potentials which predispose to reentrant ventricular arrhythmias. 
(2) Catecholamines 
The development of acute myocardial ischemia is associated with 
enhanced adrenergic activity. 
(a) Beta adrenergic receptor stimulation and cyclic AMP 
Cyclic AMP, the proposed intracellular second messenger of beta 
adrenoceptor stimulation, accumulates in the ischemic myocardium within 
10 to 30 min of coronary artery ligation. Podzuweit and associates 
(1976) have proposed a hypothesis linking this accumulation of cyclic AMP 
to the development of serious ventricular arrhythmias, such as 
ventricular fibrillation. That cyclic AMP is an arrhythmogenic agent is 
supported by the evidence summarized as follows: 
(I) Cyclic AMP accumulates in ischemic tissue before the onset of 
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ventricular fibrillation in baboon, cat and pig models (Podzuweit, 1978); 
(II) the effects of isoproterenol in increasing tissue cyclic AMP and 
precipitating ventricular fibrillation in an otherwise stable pig heart 
model with a small lateral infarct (Muller, 1981); 
(III) the dose-response curve linking increases in tissue cyclic AMP 
with the decrease in the ventricular fibrillation threshold in the 
isolated rat heart model (Lubbe et al, 1976, 1978); 
(IV) the shift of the dose-effect curve to the right and the delay in 
the rise of tissue cyclic AMP during beta-1 adrenergic stimulation by the 
beta-1 adrenergic antagonist agent, atenolol (Lubbe et al, 1978); 
(V) the opposite effects of theophylline; 
(VI) the effect of dibutyryl cyclic AMP in precipitating spontaneous 
arrhythmias in the coronary ligated rat heart (Opie, 1979); 
(VII) the effect of coronary artery ligation in the rat heart in 
elevating tissue cyclic AMP and in decreasing the fibrillation threshold 
(Thandroyen, 1982); 
(VIII) the effect of infusions of dibutyryl cyclic AMP into the edge of 
the infarct in provoking arrhythmias (Podzuweit et al, 1978); and 
(IX) the electrophysiological properties of dibutyryl cyclic AMP 
+ . especially in the presence of a high external K (Opie et al, 1979). 
Arrhythmogenic potential 
The following effects of cyclic AMP may contribute to the 
development of ventricular arrhythmias. 
(I) In partially depolarized fibres cyclic AMP promotes formation of 
slow response action potentials by enhancing transsarcolemmal calcium 
influx (Schneider & Sperelakis, 1975; Vogel & Sperelakis, 1981). 
(II) Cyclic AMP may elicit the occurrence of afterdepolarizations in 
non-automatic cells (Lazzara et al, 1978a; Daries et al, 1981). 
(III) Cyclic AMP may induce electrical uncoupling of cells in hypoxic 
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muscle (Wojtczak, 1979). 







receptor stimulation plays a 




receptor number increase in the ischemic myocardium 
within 30 min of acute myocardial ischemia (Corr et al, 1981a) during the 
phase of early ventricular arrhythmias. 
(II) An Alpha
1 
adrenoceptor antagonist, prazosin, prevents the 
early ventricular arrhythmias in the feline model of coronary artery 
ligation (Sheridan et al, 1980). 
Arrhythmogenic potential 
The following effects of adrenergic stimulation may 
contribute to the development of ventricular arrhythmias: 
(I) Alpha
1 
stimulation may evoke formation of slow respon·se action 
potentials in partially depolarized cells (Scholz, 1980). 
(II) Alpha
1 
stimulation may enhance idioventricular automaticity 
(Sheridan et al, 1980). 
(3) Free fatty acids 
Oliver et al (1968) illustrated that during acute myocardial 
infarction patients with the highest levels of plasma free fatty acids 
were more prone to develop severe ventricular arrhythmias. However, 
experimental investigation has failed to illustrate a direct 
arrhythmogenic role of free fatty acid in porcine (Most et al, 1977), 
canine (Opie et al, 1968) and rat (Didier et al, 1980) models subject to 
coronary artery ligation. 
(4) Lysophosphoglycerides 
A role for lysophosphoglycerides in the genesis of ventricular 
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arrhythmias is based on the following considerations: (a) tenfold lower 
concentrations of LPG than those calculated to occur in the ischemic 
myocardium (1.65 mM)(Gross et al, 1982) induce electrophysiological 
alterations in vitro similar to those recorded in the ischemic myocardium 
(Corr et al, 1979; Corr et al, 1981b); (b) lysophosphoglycerides induce 
ventricular arrhythmias in normoxic ventricular muscle (Man & Choy, 1982). 
Arrhythmogenic potential 
Lysophosphoglycerides may contribute to the development of 
ventricular arrhythmias by the following electrophysiological mechanisms 
(Corr et al, 1979, 1981b): 
(I) formation of slow response action potentials; 
(II) decreasing the action potential duration; 
(III) eliciting abnormal automaticity. 
(5) Acidosis 
Both metabolic (Opie, 1978) and respiratory acidosis (Khuri et 
al, 1975) occur in the ischemic myocardium. A direct relation between 
ventricular fibrillation and metabolic or respiratory acidosis has, as 
yet, not been defined. 
Arrhythmogenic potential 
(I) Severe metabolic acidosis (pH 6.1) may induce slow responses in 
Purkinje fibres (Davis et al, 1976). 
(II) Respiratory acidosis in the presence 
+ 
of extracellular K 
accumulation evokes formation of slow responses (Weiss & Shine, 1981). 
(III) 
+ . . 
H ion accumulation increases internal longitudinal resistance 
and produces electrical uncoupling of cells (Wojtczak, 1979). 
(6) Lactate 
Acute myocardial ischemia results in anaerobic glycolysis and 
hence accumulation of end product, lactate. A relation between elevated 
lactate levels and ventricular fibrillation has not been shown in the pig 
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(Muller, 1981), baboon (Podzuweit et al, 1978) and rat (Thandroyen, 1983) 
models. 
Arrhythmogenic potential 
Lactate may decrease action potential duration and also enhance 
phase 4 depolarization (Wissner, 1974). 
(F] Link between biochemical, metabolic and electrophysiological 
changes 
Thus in the first 30 min of acute myocardial infarction there 
are marked metabolic and biochemical alterations which may induce the 
following electrophysiological changes: (1) decrease in action potential 
duration, ( 2) generation of slow response action potentials or possibly 
depressed fast response action potentials, (3) afterdepolarizations. 
(1) Decrease in action potential duration 
Elevation in free fatty acid and lactate levels and reduction in 
glycolytic and mitochondrial ATP production respectively in the ischemic 
myocardium each theoretically may shorten the action potential duration. 
May 
Shortening of the action potential durationL decrease the absolute and 
effective refractory period · and may therefore be arrhythmogenic. 
However, in experimental studies neither elevated lactate nor free fatty 
acids have been linked to the initiation of ventricular arrhythmias; 
however, glucose provision may possibly be antiarrhythmic. Current 
evidence therefore does not provide much support for the abovementioned 
mechanism in the genesis of early ventricular arrhythmias. 
(2) Slow response action potential or depressed fast response 
action potential 
The development of acute myocardial ischemia is associated with 
elevation of extracellular 
+ 
+ 
K ion concentration. There is a putative 
role for K in ventricular arrhythmogenesis viz. reduction in resting 
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membrane potential with partial or complete inactivation of the fast 
sodium channel. If there is partial inactivation the ischemic action 
potential is a depressed fast response, i.e. upstroke dependent on 
+ 
transsarcolemmal Na inward current. 
+ 
If there is complete inactivation of the Na channel then 






in ventricular arrhythmogenesis viz. 
current with formation of slow 
responses. Both slow responses and depressed fast responses predispose 
to reentry which is the currently considered electrophysiological 
mechanism of early ventricular arrhythmias. 
(3) Afterdepolarizations 
Intracellular calcium overload may occur in the ischemic 
myocardium as a consequence of enhanced adrenergic stimulation, 
lysophosphoglyceride stimulation, or by inhibition of 
+ 2+ 
Na -Ca 
exchanger. Recently cytosolic calcium overload has been shown to induce 
+ 
a transient non-specific inward leak of Na ions with resultant 
development of delayed afterdepolarizations (Kass et al, 1979; Colquhoun 
et al, 1981). Such delayed afterdepolarizations may in turn induce 
ventricular arrhythmias of the triggered automaticity type (Cranefield, 
1977). 
Theoretical considerations therefore suggest a further putative 
role for calcium ions, viz. evoking afterdepolarization induced triggered 
automaticity. 
[G] Investigation of the hypothesis of ventricular arrhythmogenesis 
The hypothesis assumed is that the metabolic and biochemical 
sequelae of acute myocardial ischemia induce slow response action 
potentials or depressed fast response action potentials which predispose 
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to reentry and hence ventricular fibrillation. This thesis investigates 
the role of (a) transsarcolemmal calcium and sodium ionic inward currents 
(held to underlie slow responses or depressed fast responses), (b) 
metabolic and biochemical factors in ventricular arrhythrnogenesis during 
acute myocardial ischemia. 
The isolated Langendorff perfused rat heart was chosen as the 
experimental model because of the advantages of being able to evaluate in 
depth the role of (a) transsarcolemmal sodium and calcium inward 
currents, (b) biochemical and metabolic factors and (c) adrenergic 
receptor mediated influences on ventricular arrhythrnogenesis. 
(1) Slow response action potential 
If calcium dependent slow responses underlie early ventricular 
fibrillation then: 
(I) Calcium antagonist agents which inhibit transsarcolernrnal calcium 
inward current should prevent the occurrence of calcium dependent slow 
responses and thereby prevent early ventricular fibrillation. 
(II) Beta -adrenoceptor antagonist agents which prevent accumulation 
of cyclic AMP, should inhibit the cyclic AMP-mediated slow inward calcium 
current and thereby prevent slow responses and early ventricular 
fibrillation. 
(III) Alpha-adrenoceptor antagonist agents which prevent the 
transsarcolernrnal calcium inward current and possibly alter intracellular 
calcium distribution, should inhibit slow responses and early ventricular 
fibrillation. 
(2) Depressed fast responses 
If depressed fast responses underlie early ventricular 
fibrillation then: 
Fast channel blocking agents which inhibit the transsarcolernrnal sodium 
inward current should prevent depressed fast responses and thereby 
inhibit the occurrence of ventricular fibrillation. 
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CHAPTER 2 
EXPERIMENTAL MODEL, MATERIAL AND METHODS 
1 . EXPERIMENTAL MODEL 
[A) Isolated Langendorff perfused rat heart 
The experimental model chosen to study the mechanism of 
ventricular fibrillation during acute myocardial ischernia was the 
isolated Langendorff perfused rat heart model. The experimental animal 
model devoid of atherosclerotic coronary artery disease, lacking in 
myocardial fibrosis, subject to acute coronary artery ligation and 
species specific does not therefore exactly mimic the pattern of acute 
myocardial infarction in man. Nevertheless, the principles involved, 
irrespective of the animal model used, appear relevant in order to gain 
further insight into the mechanism of ventricular arrhythrnogenesis. 
[BJ Advantages of the model 
1. Obviation of anaesthesia and therefore the anaesthetic induced 
changes in blood pressure, heart rate and cardiac output. 
2. This model is devoid of hormonal and homeostatic reflexes 
operative in intact animals which may produce spontaneous and 
variable alterations in the vulnerability to ventricular 
fibrillation. 
3. Ventricular fibrillation usually reverts spontaneously to sinus 
rhythm. Thus repeated measurements of ventricular fibrillation 
threshold can be undertaken in the same heart. 
4. Electrical conversion of ventricular fibrillation to sinus 
rhythm is frequently unnecessary and therefore the damage caused 
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to the heart by application of large amount of electrical 
current is obviated. 
5. The electrical current applied to the isolated rat heart is 
small, the mean ventricular fibrillation threshold value of 
0,15 rnJ required (Marzagao, 1974; Lubbe et al, 1975) is 
equivalent to 1000th of the mean value of 0,3 J required in the 
open chest dog model (Allen et al, 1971; Wolff et al, 1968). 
Thus small and subtle changes in the ventricular fibrillation 
threshold can be measured in this preparation, changes not 
possible in the intact large animal. 
6. The rat is a small animal allowing for cheap accommodation and 
plentiful numbers. 
7 . The substrate supply of the heart can be maintained constant 
throughout the experiments. Moreover, hormones and 
pharmacological agents can be added to the perfusate and a 
specific concentration of an agent or hormone can be delivered 
to the myocardium. 
8. Alteration of the ionic milieu 
+ 2+ 
(K or Ca ) or substrate 
(glucose, free fatty acid) in the perfusate is easily achieved. 
9. The biochemical and metabolic profile during acute myocardial 
ischemia can be investigated in depth and correlated with 
ventricular fibrillation. 
10. The haemodynamic function of the heart can be correlated with 
ventricular fibrillation. 
[CJ Disadvantages of the model 
1. The isolated heart is devoid of autonomic nervous control. 
2. There is abnormally high coronary flow rate due to the absence 
of haemoglobin in the perfusate. 
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3. There is no peripheral circulation. 
4. The retrograde aortic perfused heart performs no volume work. 
5. The rat's action potential duration is narrow and does not vary 
with heart rate (Ypma, 1972). This is considered to be due to 
greater intracellular cycling of calcium. 
6. As in any model, effects may be species specific. 
[DJ Previous use of this model studying electrically induced 
ventricular fibrillation 
Marzagao (1974) showed that the isolated perfused rat heart was 
a suitable and stable model for study ·of the ventricular fibrillation 
threshold. 
(a) The vulnerability to ventricular fibrillation follows the trend 
described in large animal species. 
(b) The threshold values had a log normal distribution. 
(c) The energy requirements for induction of ventricular fibrillation 
were similar, notwithstanding difference in stimuli duration, viz. 2 
or 10 msec respectively. 
(d) The heart rate, ventricular fibrillation threshold and left 
ventricular pressure did not change significantly over 3 hours. 
[E] Criticism of the ventricular fibrillation threshold 
Vulnerability to ventricular fibrillation is not necessarily 
synonymous with spontaneous ventricular fibrillation and therefore one 
cannot directly extrapolate changes in the vulnerability to fibrillation 
to changes in spontaneous ventricular fibrillation. Vulnerability to 
ventricular fibrillation was proposed by Wiggers and co-workers (1940) to 
be a specific and an inherent property of the myocardium whereas Dawes 
(1952) conside·red it to represent a measurement of myocardial 
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excitability. However, Bacaner (1968), Allen et al ( 1971) and 
Gerstenblith et al (1972) proposed that alterations in ventricular 
fibrillation threshold may be accepted as a measure of the efficacy of an 
antiarrhythrnic agent. Previously Garrey (1914) proposed that the 
induction of ventricular fibrillation in myocardial tissue less than lg 
was not possible, but subsequently Willebrands and co-workers (1973) were 
able to evoke ventricular fibrillation ,in the rat and mouse heart using 
tissue less than l gram in weight and size. 
2. MATERIALS 
[A) Animals 
Long-Evans male rats (wt 250-350 g) were used for this study. 
They were anaesthetised in a glass chamber with ether, removed from the 
glass chamber, placed on a board, an incision made in the right groin to 
expose the femoral vein and 200 units of heparin injected via the femoral 
vein; after 30 seconds the chest was opened and the heart removed by 
cutting the great vessels. The heart was immediately placed in ice-cold 
Krebs-Henseleit solution to produce arrest. 
(BJ Perfusion system and perfusate 
The aorta was mounted onto a cannula and perfused at 100 cm 
water pressure according to the technique devised by Langendorff in 
1895. The time duration from opening of the chest to mounting of the 
aorta and perfusion of the heart ranged between 45 and 90 seconds. 
Perfusion fluid was Krebs-Henseleit solution, NaCl 118,5 mM, KCl 4,75 mM, 
CaC1
2 
2,50 mM, KH PO 
2 4 
1,19 mM, Mg so 
4 
1,19 mM 
25,0 mM; substrate glucose 11 mM (Krebs & Henseleit, 1932). 
and 




maintained at a pH of 7, 4. The temperature throughout the system and 
surrounding the heart was maintained constant at 37°c by way of a water 
jacket around the glassware containing the perfusion fluid. The water 
was maintained at 
0 
37 C by a thermostat apparatus, Braun Thermal Mix 2 
apparatus from Germany. The p02, pH, sodium and potassium 
concentrations were checked and were found to be within the normal 
limits. Measurements of the pH, p02 
and pco
2 
were based on the 
method of Astrup using a microelectrode unit type E5021 Radiometer, 
Copenhagen. 
[C] Electrocardiogram recording 
Continuous electrocardiograms were recorded from one electrode 
on the metal aortic perfusion cannula and a 1 cm steel wire soldered to 
the thin flexible insulated copper wire inserted superficially into the 
free wall of the right ventricle. The electrocardiogram potential was 
amplified by an ETC 8 channel of the Electronics for Medicine 
Photographic Recorder. 
The electrocardiogram with the square wave indicating the 
trigger was displayed continuously on the oscilloscope screen of the 
photographic recorder at a speed variable from 25-100 mm/sec and also 
displayed on the Electronics for Medicine Recorder. 
[D] Electrical system 
The electrocardiogram potential was amplified by an ETDA channel 
of the Electronics for Medicine Recorder. This channel has a tachometer 
and provides a synchronous output pulse. This output is coupled to a 
control box which counts the incoming synchronous pulse. After manual 
activation this trigger box delivers 7 pulse beats and on the seventh it 
starts the horizdntal sweep of a storage oscilloscope (Type 549 Tektronix 
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storage oscilloscope), whilst the 8th beat activates a Grass S88 
stimulator ( Grass Instrument Co, Massachusetts) . Once activated, the 
stimulator delivers a square wave pulse of pre-selected duration and 
delay to a constant current unit ( Grass Constant Current Unit, model 
CCULA) which allows variation of the voltage according to the resistance 
between the electrodes enabling delivery of a controlled energy impulse. 
The voltage then goes to a stimulus isolation unit which assesses and 
enables accurate delivery of the proposed current to the heart. 
[E] Left ventricular stimulation 
Two thin platinum wire electrodes inserted for electrical 
stimulation were placed horizontal and parallel at the apex and base of 
the left ventricle respectively 10 mm apart. This distance was chosen on 
the basis of previous work (Marzagao, 1974). The electrode placement was 
such that no damage to coronary vessels occurred. The cathode was placed 
at the base just under the atrioventricular groove and the anode inserted 
at the apex. 
3 . METHODOLOGY 
[A] Ventricular fibrillation threshold 
Ventricular fibrillation threshold was obtained by the train 
method of electrical stimulation. This consists of delivery of 10 square 
wave pulses distributed evenly over the duration of 200 msec stimulation 
and commenced after a delay of 10 msec after the trigger obtained from 
the initial pulse of the R wave. Each pulse duration was 20 msec 
consisting of 2 msec impulse and 18 msec delay between the pulses. The 
train method differs from the single stimulus method for measurement of 
ventricular fibrillation threshold. The single stimulus method of 
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electrical stimulation involves input of a single pulse progressively 
scanning the T wave by increasing the delay from the triggering point of 
the QR wave. Experiments (in our laboratory) have demonstrated there to 
be no difference in ventricular fibrillation threshold levels obtained by 
either train or single stimulus method of electrical stimulation. 
[B J Criteria for ventricular fibrillation and measurement of 
ventricular fibrillation threshold 
Ventricular fibrillation was defined as repetitive irregular 
ventricular rhythm which persisted for more than 6 cycles. This pattern 
was associated with profound lowering of the left ventricular pressure 
with loss of the left ventricular pressure wave, thus fulfilling the 
criteria required for ventricular fibrillation, namely, electrical 
abnormality of the heart associated with mechanical failure. Ventricular 
fibrillation usually reverts spontaneously to sinus rhythm. If 
ventricular fibrillation persisted for longer than 15 sec hearts were 
defibrillated using ice-cold Krebs-Henseleit solution or if this failed, 
by DC electrical conversion. Ventricular fibrillation threshold value 
was expressed in mJoules as this is most representative because it 
incorporates the current, the voltage and stimulus duration permitting 
acceptable comparison of values obtained in same or different species, 
even when different stimulation voltages are required. The ventricular 
fibrillation threshold was estimated using an initial current of 4, 0 rnA 
and progressively increasing the current in steps of 2,0 rnA until 
ventricular fibrillation occurred. The ventricular fibrillation 
threshold was defined as the lowest current required to produce 
ventricular fibrillation on more than 2 occasions. The ventricular 
fibrillation threshold values in control hearts ranged between 5 rnA and 
13 rnA with the mean value approximately 9 rnA. 
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[CJ Protocol prior to coronary artery ligation 
After mounting the heart, there was a stabilization period of 
15 min after which the coronary flow rate, heart rate and ventricular 
fibrillation threshold was measured in each experiment. The coronary 
flow rate was measured by collecting the coronary effluent in a graduated 
measuring tube over 30 to 60 sec. Coronary flow rates for control hearts 
ranged from 6 to 13 ml/min depending on the size of the heart; the heart 
rate ranged between 200 to 300 beats/min. The ventricular fibrillation 
threshold levels were between 5 to 13 mA; hearts with thresholds above 
or below these levels were excluded from the study. 
After an intervening period of 10 minutes, repeat coronary flow 
rates, heart rates and ventricular fibrillation threshold levels were 
measured. 
In those series in which pharmacological agents were evaluated, 
the protocol was identical except that the agent was infused or perfused 
during the 10 min intervening period and subsequently throughout the 
experiment. 
(DJ Protocol during coronary artery ligation 
Acute regional myocardial ischemia of the left ventricle was 
produced by ligation of the left main coronary artery within 2 nun of 
where it emerges below the left atrium (Kannengiesser et al, 1975). 
Successful ligation of the coronary artery was evident when there was 
reduction in the total coronary flow rate by at least 25% and a grey blue 
discolouration developed over the left ventricular free wall. Heart rate 
was recorded continuously and coronary flow rates measured two to four 
times during the 15 min period of ischemia. The ventricular fibrillation 
threshold was measured during the first 15 minute period of acute 
myocardial ischemia because the trough or nadir of the ventricular 
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fibrillation threshold is reached 10 to 15 minutes after coronary artery 
ligation. In a separate series of experiments, the ventricular 
fibrillation threshold was evaluated during the 15 minute period of acute 
regional myocardial ischernia with added adrenergic stimulation i.e. 
adrenaline 5 X 
-7 
10 M. This series of experiments was undertaken 
because the development of acute myocardial ischemia in the in vivo 
situation is associated with ( i) an increase in circulating level of 
catecholamines, principally adrenaline (peak concentration in man 5 x 
-9 
10 M, ( Jewi tt et al, 1969) ) and (ii) release of noradrenaline in the 
ischemic myocardium (peak concentration in animal 10 -SM (Dietz et al, 
1981)). The chosen concentration of adrenaline viz 
-7 . 
5 x 10 M therefore 
provides adequate adrenergic stimulation. At the end of the experiment, 
disulphan blue dye was introduced into the cannula immediately above the 
heart. This dye combines with oxygen, hence the non-ischemic myocardium 
is stained blue and the ischemic myocardium is unstained. The heart was 
then freeze-clamped with Wollenberger clamps (1960) pre-cooled in liquid 
nitrogen for biochemical analysis. Separation of the ischernic and 
non-ischemic tissue was then undertaken. 
[E) Chemicals 
All drugs were used in the form of racernic compounds, the 
exceptions being the isomers of verapamil and of propranolol. 
Drug 
verapamil hydrochloride 


































Knoll, West Germany 
Dr W G Nayler, Australia 
Bayer Chemicals, West Germany 
Tanabe Seikayu, Tokyo 
Ciba Geigy, South Africa 
ICI, South Africa 
ICI, South Africa 
ICI, South Africa 
Pfizer, South Africa 
Sigma, USA 
Boots, South Africa 
Ciba, South Africa 
Keatings, South Africa 
Sigma, USA 
Taueber & Carsen, S Africa 
Results are expressed as mean + standard error of the mean for 
the number of the experiments. The number ( n) of hearts in each series 
ranged from 5 to 16. Probability [p) values were calculated with either 
(a) one way or two way analysis of variance or (b) students t test 
(paired or unpaired) using two-tailed values corrected for unequal 
variances. Probability values less than 0,05 indicated significant 
difference between mean values. 
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[G] Biochemical analysis 
Hearts were freeze-clamped with Wollenberger clamps and freeze 
dried for 48 hours in an Edwards Modulyo freeze-drier. The freeze-dried 
hearts, weighing approximately 100 mg were homogenised in 6% perchloric 
acid with an Ultra-turrax homogeniser. The extracts were centrifuged and 
the supernatant neutralised with tris/KOH buffer to pH 7, 0 and used for 
analysis. 
Adenosine triphosphate (ATP), phosphocreatine (PCr) were assayed 
in neutralised extracts. All compounds were assayed enzymatically by 
spectre-photometric methods. Standards, internal standards and blanks 
were included in every assay. 
1. Adenosine triphosphate (Lampbrecht and Trautschold, 1974) 
The assay is based on the following reaction: 
ATP + glucose 










The change in extinction at 340 nm was noted on the addition of 
hexokinase 5 pl (10 mg/ml) to 0,2 ml tissue extract, mixed with 2,8 
ml assay medium, containing: 
MgCl 
2 
0 , 10 ml ; tris buffer 0,2M (pH 7,5) 1,00 ml; NADP 1% w/v 
0,10 ml; glucose 100 mM 0,05 ml; H2
o dist 1,55 ml; G6PDH 1 mg/ml 
0, 005 ml. 
0,05 ml ADP (lOmM) is then added to provide sufficient ADP for 
subsequent assay of PCr and any further change in extinction is noted. 
2. Phosphocreatine (Lampbrecht and Trautschold, 1974) 
The assay is based on the following reaction: 




The further change in extinction at 340 nm (on addition of 10 pl 
creatine phosphate kinase (10 mg/ml) after 30 min is proportional to 
the amount of PCr present. 
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3. Glycogen (Good et al, 1933) 
The glycogen level was determined by the method described by Good et 
al (1931). The tissue is first digested with 40% KOH and heat. The 
glycogen in the digested tissue was precipitated with cold ethanol. 
The glycogen is hydrolysed to its glucose components with 2N HCl and 
heat (96°C). The extract was then neutralised and assayed 
enzymatically by a spectrophotometric method. Standards, internal 
standards and blanks were included in every assay. The assay is 
based on the following reaction using hexokinase (HK) and glucose 6 
phosphate dehydrogenase (G6PDH). 
Glucose + ATP HK G6P + ADP 
~ 
>, 




The change in extinction at 340 nm was noted at the addition of HK 
and G6PDH to tissue extract and 2,8 ml of assay medium. The increase 
in NADPH measured, is proportional to the amount of glucose present 
thus glycogen is originally present. 
4. Cyclic AMP 
Cyclic AMP (cAMP) was measured by the method described by Tovey et al 
(1974). This competitive protein binding assay is based on the 
following principle: 
If a stable compound A is introduced into a system which contains a 
constant amount of radioactive compound A* and is binding to protein 
P, A will displace A* from the protein binding sites, in proportion 
to its concentration. 
p + A* 
' > 




p + A < > p A (unlabelled complex) 
The amount of radioactivity bound in the labelled complex decreases 
as the amount of unlabelled compound is increased. Cyclic AMP in the 
sample and a fixed quantity of tritium labelled cyclic AMP compete 
for binding to a protein with high specificity and affinity for 
cyclic AMP. The amount of labelled cyclic AMP - protein complex 
formed is inversely proportional to the amount of unlabelled cyclic 
AMP in the sample. The unbound nucleotide is removed by a 
precipitation reaction using activated charcoal. A supernatant, 
containing the bound nucleotide is obtained by centrifugation and 
removed for scintillation counting. A standard curve is 
constructed. Co/Cx is plotted against concentration of cyclic AMP in 
the standard dilutions. Co: labelled nucleotide bound in the 
absence of unlabelled nucleotide. Cx: labelled nucleotide bound in 
the presence of a standard quantity of unlabelled nucleotide. 
Assay kit contains: Tris/EDTA buffer; purified bovine muscle 
protein; cyclic AMP; cyclic AMP standard; charcoal 




CATECHOLAMINE INDUCED VENTRICULAR FIBRILLATION 
1. RATIONALE FOR INVESTIGATION OF CATECHOLAMINE INDUCED VENTRICULAR 
FIBRILLATION 
Several lines of evidence link enhanced adrenergic activity to the 
genesis of ventricular fibrillation during acute myocardial infarction 
(Ceremuzynski et al, 1969; Jewitt et al, 1969). Adrenaline induces 
myocardial electrophysiological alterations similar to those present 
during acute myocardial infarction (Gilmour & Zipes, 1980) and also 
increases the myocardial vulnerability to ventricular fibrillation (Lubbe 
etal, 1978). 
A logical approach in our understanding of ventricular 
arrhythmogenesis during acute myocardial infarction is to first define 
the mechanism of catecholamine-induced ventricular fibrillation. Lubbe 
and co-workers (1978) proposed that cyclic AMP, the reputed intracellular 
second messenger of beta-receptor stimulation, mediates the 
arrhythmogenic effect of adrenergic stimulation. Cyclic AMP promotes 
calcium ion influx during the slow phase of the action potential 
(Schneider & Sperelakis, 1975; Vogel & Sperelakis, 1981); hence a 
further implication has been that calcium ions play a role in the genesis 
of ventricular fibrillation, possibly by induction of abnormal slow 
responses or by afterdepolarizations. 
If this hypothesis is correct then it might be anticipated that: 
1) beta-adrenoceptor antagonist agents should prevent catecholamine 
induced ventricular fibrillation by inhibiting the accumulation of cyclic 
AMP; 
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2) calcium antagonist procedures should prevent catecholamine induced 
ventricular fibrillation by inhibiting the transsarcolenunal calcium ion 
influx. 
I therefore investigated the effect of beta-adrenoceptor antagonist 
procedures and calcium antagonist procedures on adrenaline induced 
ventricular fibrillation in the non-ligated heart. 
2. RESULTS 
[A] Control series 
In 8 control hearts the mean heart rate was 250 !_ 10 beats/min, 
the average coronary flow was 9. 0 + 0. 5 ml/min and the ventricular 
fibrillation threshold was 10.0 + 0.3 mA. Biochemical analysis revealed 
the following metabolic status: adenosine triphosphate 3.9 !_ 0.2 umol/g, 
phosphocreatine 4.5 + 0.6 umol/g and cyclic AMP 0.44 + 0.02 nmol/g. 
[BJ Concentration response of adrenaline (Table 3-1) 
The effect of adrenaline 
-7 
5 x 1 O M on heart 
rate, coronary flow rate, ventricular fibrillation threshold, cyclic AMP 
and high energy phosphate is depicted in Table 3-1. Adrenaline caused a 
concentration dependent increase in both the coronary flow rate and heart 
rate; the maximum increment in the coronary flow occurred with 5 x 
-7 
10 M. Adrenaline 5 X to 5 X evoked a concentration 
dependent reduction in the ventricular fibrillation threshold and a 
corresponding increment in the tissue levels of cyclic adenosine 
monophosphate. 
According to the dose response curve of adrenaline 5 x 10 -SM to 5 
X 
-7 
10 M, adrenaline 5 X 
-7 
10 M caused ( i) the greatest reduction in 
ventricular fibrillation threshold 10. O + O, 3 to 3.1 + 0,8 mA 
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(p <0. 0001), (ii) maximum increase in the tissue level of cyclic AMP, 
0.44 + 0.02 to 0.91 + 0.03 nmol/g (p <0.001), (iii) depletion of ATP 
content 3.9 + 0.2 to 3.1 + 0.3 umol/g (p< 0.05) and (iv) loss of 
myocardial glycogen stores 14 + 2 to 2.0 + 0.2 umol glucose equivalent/g 
(p <0.00l)(Fig 3-2). 
[C] Effect of beta-adrenoceptor antagonism on adrenaline-induced 
changes 
-5 
Atenolol 5 x 10 M produced a greater than 10-fold shift to 
the right of the log concentration effect curves for isoproterenol on 
heart rate thereby indicating effective beta-adrenoceptor antagonism 
(Fig 3-1). 
-5 
Atenolol 5 x 10 M inhibited the increase in heart rate and 
coronary flow rate and also prevented the fall in the ventricular 
fibrillation threshold during adrenaline 5 X 
-7 
10 M stimulation 
(Table 3-2); 
-5 
in addition atenolol 3.8 x 10 M inhibited the adrenaline 
induced cyclic AMP accumulation (Lubbe et al, 1978). 
[D] Effect of beta-adrenoceptor antagonism on dibutyryl cyclic AMP 
induced changes (Table 3-3) 
Dibutyryl cyclic AMP 1. 5 x l0-
4
M, the analogue of cyclic AMP 
which enters the cell more easily, decreased the ventricular fibrillation 
threshold from 7. 7 + 1. 3 to 3. 4 + 1. 0 mA (p <0. 02) and increased the 
coronary flow rates 9. 7 + 0.5 to 19.1 + 1.6 mls/min (p < 0.02). 
-5 
Beta-adrenoceptor antagonism with atenolol 5 x 10 M did not prevent 
the dibutyryl cyclic AMP induced fall in the ventricular fibrillation 
threshold, 2.9 + 0.7 vs 3.4 + 1.0 mA (NS) nor did it alter the coronary 
flow rate, 17.8 + 1.3 vs 19.l + 1.6 mls/min (NS). 
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[El Effect of calcium channel antagonist agents on adrenaline 
induced changes (Table 3-4) 
Both verapamil and nifedipine were subject to a dose response 
curve to assess the effect in producing coronary artery vasodilation and 
slowing of the heart rate. Veraparnil 1.5 X 
-7 
10 M and nifedipine 
-6 
10 M produced maximum coronary artery vasodilation and induced 
bradycardia, thereby manifesting effective calcium antagonism . 
Nifedipine attenuated the positive chronotropic effect of adrenaline 5 x 
l0-
7
M by approximately 15% but did not enhance the increase in coronary 
flow induced by adrenaline. Verapamil 1. 5 x l0-
7M, nifedipine l0-
6M 
completely prevented the adrenaline-induced vulnerability to ventricular 
fibrillation: 10.9 + 1.4 (p <0.05), 8.7 + 1.4 (p< 0.05) respectively 
versus adrenaline 5 x l0-
7
M, 3.1 + 0.8 rnA. 
To further delineate the mechanism of the ventricular 
antiarrhythrnic activity of verapamil, investigation was undertaken with 
1(-) and d(+) verapamil isomers. 
[Fl Effect of 1(-) and d(+) isomers of veraparnil on 
(i) Guinea-pig papillary muscle (Tables 3-5, 3-6) 
1(-) veraparnil decreased the action potential duration (at 90% 
repolarization of the normal transmernbrane action potential) and also 
antagonised calcium dependent slow response action potentials in the 
isolated superfused guinea-pig papillary muscle. d(+) verapamil produced 
no alteration of action potential duration of the transmembrane action 
potential or of slow response action potential. These findings indicate 
that 1(-) veraparnil is quantitatively the active isomer in inhibiting the 
slow calcium inward current. 
(ii) Rat heart (Figure 3-2) 
Both 1(-) and d(+) veraparnil 1.5 x l0-
7
M inhibited the 
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adrenaline 5 x 10 M induced increment in the heart rate response: 328 
+ 11, 333 + 13 versus 370 + 6 beats/min ·(p< 0.05, p <0.05), but left the 
enhanced coronary flow rates unchanged: 18. 0 + 0. 3 versus 18. 4 + 0. 4 
ml/min. 1(-) Verapamil but not d(+) verapamil prevented the 
adrenaline-induced reduction in the ventricular fibrillation threshold: 
1(-) verapamil 10.8 + 1.0 mA (p <0.01), d(+) verapamil 2.0 + 0.5 mA (NS) 
versus adrenaline 5 X 
-7 
10 M 3.1 + 0.8 mA. Both isomers of verapamil 
ameliorated the adrenaline-induced depletion of tissue ATP levels, but 
were ineffective in preventing the marked breakdown of myocardial 
glycogen stores. In keeping with the latter finding, neither 1 (-) nor 




verapamil 0.94 + 0.04 nmol/g, d(+) 









Effect of reduction in extracellular Ca concentration on 
adrenaline induced changes (Table 3-4) 
To further clarify the role of the transsarcolemmal calcium 
current in adrenaline induced ventricular fibrillation, the effect of 
reduction in extracellular calcium concentration was analysed. Reduction 
in perfusate 
2+ 
Ca ion concentration from 2.5 mM to 1. 25 mM or to 
1. 00 mM completely prevented the adrenaline induced fall in ventricular 
fibrillation threshold. Control (perfusate ca2+ 2.5 mM) 10.0 + 
0.3 mA; adrenaline 5 X l0-
7M + perfusate Ca 2+ 2.5 mM, 3.1 + 0.8 mA; 
adrenaline 5 X l0-
7M + perfusate Ca
2+ 1.25 mM, 18.6 + 3.9 mA; 
adrenaline 5 X l0-
7M + perfusate 
2+ 
27.3 Ca 1. 0 mM, + 5 .1 mA. 
Coronary flow rates and heart rates are depicted in Table 3-4. 
[HJ Effect of calcium channel antagonist agents on dibutyryl 
cyclic AMP induced changes (Table 3-7) 
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The next question to address was whether calcium antagonists 
were effective in preventing the enhanced vulnerability to ventricular 
fibrillation induced by cyclic AMP, the reputed intracellular second 
messenger of beta-adrenergic stimulation. Dibutyryl cyclic AMP 1. 5 x 
-4 
10 M, the analogue of cyclic AMP which penetrates the cell membrane 
more easily, decreased the ventricular fibrillation threshold from 7.7 + 
1.3 to 3.4 + 1.0 mA (p< 0.02), increased the coronary flow rates from 9.7 
+ 0.5 to 19.1 + 1.6 ml/min (p < 0.02) but did not produce any alteration 
in the heart rate. Both verapamil 1. 5 x l0-
7
M and nifedipine l0-
6
M 
prevented the dBcAMP induced fall in the ventricular fibrillation 
threshold, but each agent did not prevent the dBcAMP induced increase in 
coronary flow rates. Both nifedipine and verapamil reduced heart rate. 
3. DISCUSSION 
[A) Electrophysiological effects of adrenaline 
Adrenaline in supraphysiological concentrations induces, in the 
normoxic rat myocardium, electrophysiological alterations which 
predispose to ventricular arrhythmias. These electrophysiological 
alterations include: (i) reduced resting membrane potential, action 
potential amplitude and duration; (ii) conduction disturbances such as 
conduction delay, unidirectional block, summation and inhibition and 
(iii) abnormal automatic activity including triggered sustained rhythmic 
activity (Gilmour & Zipes, 1980). 




The arrhythmogenic effect of adrenaline is shown by
 its ability 
to enhance the vulnerability to ventricular fibrill
ation in the isolated 
non-ligated rat heart. The adrenaline 
induced vulnerability to 
ventricular fibrillation has been previously link
ed to accumulation of 
myocardial cyclic adenosine monophosphate (Lubbe e
t al, 1976; Lubbe et 
al, 1978). The evidence of the study does not show
 a correlation between 
reduction in ventricular fibrillation threshold 
and accumulation of 
myocardial cyclic AMP. Specifically, adrenali
ne 5 x 10-
8
M markedly 
increased cyclic AMP content but did not alter 
the vulnerability to 
ventricular fibrillation. Cyclic AMP accumul
ation may therefore reflect 
an epi -phenomenon . Beta-adrenoceptor antagonism
 with atenolol prevents 
the adrenaline induced fall in ventricular fib
rillation threshold. 
Dibutyryl cyclic AMP, the analogue of cyclic AMP 
which penetrates the 
cell membrane more easily, enhances the vulner
ability t o ventricular 
fibrillation; this arrhythmogenic effect is
 not inhibited by 
beta-adrenoceptor antagonism. The beta-adre
noceptor is therefore 
implicated in the genesis of ventricular fibrillatio
n induced by enhanced 
adrenergic stimulation. The arrhythmogenic 
effect of adrenergic 
stimulation may not be mediated by cyclic AMP
, notwithstanding the 
ability of dibutyryl cyclic AMP to induce ventricul
ar fibrillation. 
[Cl Cyclic AMP, calcium antagonist procedures and v
entricular 
fibrillation 
Calcium channel antagonist agents and a red
uction 
extracellular calcium concentration complet
ely prevented 





effect occurred even though there was no reduct
ion in the . myocardial 
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content of cyclic AMP. This finding further 
dissociates changes in 
cyclic AMP from alterations in vulnerability to ventricul
ar fibrillation 
and indicates that cyclic AMP is not the fina l messenger 
of ventricular 
fibrillation. However, a further interpr
etation is that calcium 
antagonists may mediate protection against ventricula r fib
rillation at a 
site distal to the beta-adrenoceptor-adenylate cyclase-cy
clic AMP chain 
of events. Support for this inference stems from the fin
ding that both 
verapamil and nifedipine were able completely to preven
t the enhanced 
vulnerability to ventricular fibrillation evoked · by the 
cAMP analogue, 
dibutyryl cyclic AMP. 
Are these findings compatible with the proposed hypothesis
 that 
the transsarcolemmal calcium current plays a major role i n 
the genesis of 
catecholamine-induced ventricular fibrillation? The a
bove data do not 
provide direct proof for this hypothesis because calc
ium antagonist 
agents not only inhibit transsarcolemmal calcium i nflux b
ut also produce 
a variety of effects, each of which may be responsible 
for ventricular 
antiarrhythmic activity. ( i) Coronary artery vasodi lati
on ( Fanburg et 
al, 1964); (ii ) preservation of metabolic status (Weber, 1
959); (iii ) 
and alpha
2 
adrenoceptor antagonist activity (Nayler et a l , 
1982 ) and (iv ) sodium channel antagonist activity (Bayer et
 al, 1975 ) . 
[D J Calcium and ventricular fibrillation 
That calcium ions mediate catecholamine induced ventri
cular 
fibrillation is suggested by the following arguments: Fir
st, a reduction 
in the calcium ion concentration in the perfusion fl
uid completely 
prevented the adrenaline induced vulnerability t
o· ventricular 
fibrillation. Secondly, 1 (-) verapamil, the isomer of verapa
mil which 
inhibited the slow calcium channel without altering th
e fast sodium 
channel, antagonised the catecholamine induced vulnerabil
ity to 
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ventricular fibrillation. Thirdly, nifedipine which does not interact 
with either alpha or alpha adrenoceptors (Motulsky et al, 1983) and 
1 2 . 
is therefore a 'pure calcium antagonist' protected against the adrenaline 
induced ventricular fibrillation. Fourthly, protection was not due to 
preservation of myocardial high energy phosphate content or glycogen 
stores. Fifthly, a clear dissociation could be shown between the effects 
on coronary flow rates and on antiarrhythmic activity. 
These findings suggest that calcium ions mediate catecholamine 
induced ventricular fibrillation. 
4. CONCLUSIONS 
l. Beta-adrenoceptor antagonist agents completely prevent the 
adrenaline induced vulnerability to ventricular fibrillation. The 
beta-adrenoceptor is directly implicated in the genesis of such 
ventricular fibrillation. Cyclic AMP, the proposed intracellular second 
messenger of beta-receptor stimulation, does not appear to mediate the 
arrhythmogenic effect of enhanced adrenergic activity, rather cyclic AMP 
accumulation may reflect an epi-phenomenon. 
2 . Calcium antagonist procedures completely prevent the 
adrenaline-induced vulnerability to ventricular fibrillation. Calcium 
ions may act as the intracellular second messenger in mediating the 
ventricular arrhythrnogenic effect of enhanced adrenergic stimulation. 
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Figure 3-1 LOG CONCENTRATION EFFECT CURVES FOR ISOPROTERENOL 
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Table 3-1 Adrenaline-mediated changes in the non-ligated rat 
heart 
Control 
Heart rate (beats/min) 250 346** 
+10 +12 
Coronary flow (ml/min) 9.0 17,8** 
+0.5 _2:0 I 5 
VFT (rnA) 10.0 8,4 
+0.3 +1,3 
ATP (urnol/g fresh weight) 3.9 
+0.2 
cAMP (nrnol/g fresh weight) 0.44 0,73** 
+0.02 _2:0,05 
Number of hearts= 6-15 in each series 
p values: adrenaline vs control in each instance 
* p <0.05 













Table 3-2 Effect of beta-adrenoceptor antagonist - atenolol -
on adrenaline induced changes in the non-ligated 
rat heart 
Control Adrenaline 5 x 10-7M 
n 8 15 
Heart rate 250 370** 
(beats/min) +10 +6 
Coronary flow 9.0 17.4** 
(ml/min) +0.5 +0.4 
VFT 10.0 3.1* 
(mA) +0.3 +0.8 
n = number of hearts 
Values represent Mean+ SEM 
p values adrenaline or atenolol + adrenaline vs control 
* p < 0, 05 
**p< 0,001 
Atenolol 5 x 10-5M 
+ 









Table 3-3 Effect of atenolol 5 x 10-5M on dibutyryl 
cyclic 
AMP 1.5 x 10-4M induced changes 
Control dBcAMP 1.5 X 10-4
M 
VFT1 HR1 CF1 VFT2 HR2 ~2 
(rnA) (beats/min) (mls/min) (rnA) (beats/min) (mls/min) 
7.7 268 9.7 3,4* 258 19.1* 
+1. 3 +13 +0.5 +1. 0 +13 +1.6 
Control dBcAMP 1.5 X 10-4M 
+ atenolol 5 X 10-SM 
VFT1 HR1 CF1 VFT2 HR2 CF2 
(rnA) (beats/min) (mls/min) (rnA) (beats/min) (mls/min) 
8.5 288 8.8 2,9* 265 17.8* 
+0.8 +12 +0.4 +0.7 +13 +1.3 
Values represent Mean..:!:. SEM 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3-6 Effect of d(+) and 1(-) isomers of verapamil 1.5 x 10-7M 
on slow response action potentials of guinea-pig papillary 
muscle 
Slow response amplitude Slow response duration 
at 90% repolarization 
(msec) (mV) 
Control (n=l2) 69 + 3.33 -
Without drug 
20 min (n=4) 176.:!:_ 3.43 
p < 0. 01 
1(-) verapamil L35 20 min (n=4) + 6.99 
d(+} verapamil 
20 min (n=4) 70 + 2.64 -
Slow response action potential: 
18 mM K+ depolarized guinea-pig 
isoproterenol. 
Stimulation rate 30/min. 
Variable stimulus voltage. 
Values represent Mean+ SEM 
101 + 4.43 
110 + 4.081 
p(0.01 P<. 0 .01 
I 48 + 7.82J 
101 + 4.27 
papillary muscle plus 
3-18 
Table 3-7 Effect of verapamil 1.5 x 10-7M and nifedipine 10-6M 
on dibutyryl cyclic AMP induced changes in the isolated 
non-ligated rat heart 
Control 
VFT1 HR1 CF1 VFT2 
(mA) (beats/min) ( mls/min) (mA) 
7.7 268 9.7 3.4** 
+1.3 +13 +0.5 +1.0 
Control 
~l HR1 CF1 VFT2 
(mA) (beats/min) (mls/min) (rnA) 
13.0 256 9.7 12.2 
+1.0 +15 +0.3 +1.2 
Control 
VFT1 HR1 CF1 VFT2 
(mA) (beats/min) ( mls/min) (rnA) 
8.7 256 8.0 6.0 
+1.2 +9 +0.4 +1.0 
Values represent Mean+ SEM 
* p <0.05 paired t-test 2 vs 1 in each instance 
** p <0. 02 





dBcAMP 1. 5 X 10-4M 





dBcAMP 1.5 X 10-4M 






BETA-ADRENOCEPTOR ANTAGONIST AGENTS AND VULNERABILITY TO 
VENTRICULAR FIBRILLATION DURING ACUTE REGIONAL 
MYOCARDIAL ISCHEMIA 
1. PROPOSED ROLE OF BETA ADRENERGIC RECEPTOR AND CYCLIC AMP IN 
VENTRICULAR FIBRILLATION 
4-1 
Enhanced adrenergic activity increases the vulnerability to 
ventricular fibrillation in the non-ischemic rat heart (Lubbe .et al, 
1978). Opie and co-workers ( 1981) have provided evidence that cyclic 
AMP, the intracellular second messenger of beta-receptor stimulation, 
mediates the arrhythmogenic effect of enhanced adrenergic activity in the 
non-ischernic rat heart. The development of acute myocardial ischemia is 
associated with an increase of the circulating levels of noradrenaline 
and adrenaline (Ceremuzynski et al, 1969), probable release of 
noradrenaline from the ischemic myocardium (Hirche et al, 1980) and 
accumulation of cyclic AMP (Podzuweit et al, 1978; Corr et al, 1978) in 
the ischemic myocardium. Podzuweit and co-workers (1978) illustrated a 
temporal relationship between cyclic AMP accumulation in the ischemic 
myocardium and onset of ventricular fibrillation during acute myocardial 
ischemia. It has, therefore, been argued that cyclic AMP mediates the 
arrhythmogenic effect of enhanced adrenergic activity during acute 
myocardial ischemia. It has been further proposed that in ischemic 
myocardial cells, partially depolarized by extracellular potassium 
accumulation, cyclic AMP may act as an arrhythmogenic agent by promoting 
the transsarcolemrnal calcium inward current, thereby predisposing to slow 
response action · potentials and reentrant ventricular arrhythmias. If 
4-2 
this hypothesis is correct, then beta-adrenoceptor antagonist agents 
should prevent cyclic AMP accumulation, indirectly inhibit 
transsarcolemmal calcium ion influx and thereby prevent the occurrence of 
slow response action potentials and ventricular arrhythmias. I therefore 
investigated the effect of beta-adrenoceptor antagonist agents on the 
vulnerability to ventricular fibrillation during acute myocardial 
ischemia. 
2. RESULTS 
[A] Coronary artery ligation (Tables 4-1, 4-2, 4-3) 
Ligation of the left main coronary artery decreased the heart 
rate, 243 + 10 to 199 + 14 beats/min (p<0.02) and also the total 
coronary flow rate 7.8 + 0.5 to 3.9 + 0.5 ml/min (p <0.01). There was a 
marked fall in the ventricular fibrillation threshold, the trough being 
reached 10 to 15 min after coronary artery ligation. VFT values: 
preligation 10. 0 + 0. 3 mA, 15 min coronary artery ligation 2. 0 + 0. 3 mA 
(p< 0.01). At the nadir of the ventricular fibrillation threshold (i.e. 
15 min after coronary artery ligation) depletion of adenosine 
triphosphate, phosphocreatine and glycogen was evident in the ischemic 
myocardium. In addition, there was accumulation of lactate and cyclic 
AMP in the ischemic myocardium. In a separate series of experiments, the 
-7 
simultaneous infusion of adrenaline 5 x 10 M during left main coronary 
artery ligation increased the heart rate and total coronary flow rate 
(p < O. 01 in each case) and further enhanced the vulnerability to 
ventricular fibrillation during the period of acute myocardial ischemia; 
-7 




Atenolol 5 x 10 M produced a greater than 10-fold shift to 
the right of the log concentration effect curves for isoproterenol on 
heart rate thereby indicating effective beta-adrenoceptor antagonism 
(Fig 4-1). 
Atenolol 5 x l0-5M to l0-4M, however, did not prevent the 
fall in ventricular fibrillation threshold during acute myocardial 
ischemia (Fig 4-2) nor did it alter the heart rate or coronary flow rate 
during this period (Table 4-1). Moreover, atenolol did not prevent the 
depletion of adenosine triphosphate or phosphocreatine or inhibit the 
accumulation of cyclic AMP in the ischemic myocardium (Lubbe et al, 1981) . 
Atenolol 5 x l0-
5
M maintained higher ventricular fibrillation 
threshold levels during the first ten minutes of acute myocardial 
ischemia with concomitant adrenaline 5 x 10-?M stimulation; however, 
at 15 min (i.e. the period of maximum vulnerability to ventricular 
fibrillation) protection was not evident (Fig 4-3). 
[CJ Metoprolol 
Metoprolol l0-
6M and l0-5M produced a greater than 10-fold 
shift to the right of the log concentration effect curves for 
isoproterenol on heart rate thereby indicating effective 
beta-adrenoceptor antagonism (Fig 4-4). Metoprolol l0-
5
M, however, did 
not prevent the fall in ventricular fibrillation threshold during acute 
myocardial ischemia (Fig 4-5), nor did it produce any alteration in the 
coronary flow rate or heart rate during this period (Table 4-1). 
Moreover, metoprolol l0-
5
M did not prevent the depletion of ATP or PCR 
in the ischemic myocardium (Table 4-2) or inhibit the accumulation of 
cyclic AMP in the ischemic myocardium (Table 4-3). However, a 10-fold 
higher concentration, metoprolol l0-
4M, increased the ventricular 
4-4 
fibrillation threshold before coronary artery ligation, and also 
maintained higher ventricular fibrillation threshold levels during acute 
myocardial ischemia (Fig 4-5). This protective effect was associated 
with lower tissue cyclic AMP levels both in the non-ischemic and ischemic 
myocardium (Table 4-3). A reduction in heart rate was evident before and 
after coronary artery ligation; total coronary flow rates were no 
different from the control series subject to coronary artery ligation 
(Table 4-1). 
[D] dl-Propranolol 
dl-Propranolol, 5 X 
-6 
10 M attenuated the fall in the 
ventricular fibrillation threshold during acute myocardial ischemia 
(Fig 4-6). The ventricular antiarrhythmic effect of propranolol could 
not be linked to alteration either in the coronary flow rate or heart 
rate during acute myocardial ischemia (Table 4-1). In work emanating 
from this laboratory, Lubbe and co-workers (1981) showed that 
dl-propranolol 8 X 
-5 
10 M exhibited ventricular 
antiarrhythmic activity but did not preserve adenosine triphosphate or 
phosphocreatine levels in the ischemic myocardium. However, 
-6 -5 
dl-propranolol 8 x 10 M and 1. 6 x 10 M reduced cyclic AMP levels in 
the ischemic myocardium. 
[E] d(+) Propranolol 
The effect of dl-propranolol on the fall in ventricular 
fibrillation threshold after coronary artery ligation was further 
investigated using the d(+) isomer of propranolol. d(+) Propranolol 5 x 
l0-6M attenuated the fall in the ventricular fibrillation threshold 
during acute myocardial ischemia (Fig 4-6). The ventricular 
antiarrhythmic action of d(+) propranolol could be linked to reduction in 




[A) Beta receptor antagonism with atenolol, metoprolol and 
propranolol 
Beta-adrenoceptor antagonism with atenolol 5 X 
-5 
10 M and 
metoprolol l0-5M was ineffective in preventing the fall in ventricular 
fibrillation threshold during acute myocardial ischemia. 
Beta-adrenoceptor antagonism with atenolol 5 X l0-
5
M attenuated the 
fall in the ventricular fibrillation threshold during the first 10 min of 
acute myocardial ischemia with concomitant adrenergic stimulation; 
however, this protective effect was not maintained at 15 min, i.e. the 
time of maximum vulnerability to ventricular fibrillation. In 
concentrations higher than that required to produce beta-adrenoceptor 
antagonism, metoprolol 
-4 -4 
10 M but not atenolol 10 M prevented the 
fall in the ventricular fibrillation threshold during acute myocardial 
ischemia. Ventricular antiarrhythmic activity was not due to reduction 
in heart rate, maintenance of total coronary flow rates or preservation 
of metabolic status (Lubbe et al, 1981). Further investigation utilizing 
the d ( +) isomer of propranolol 5 x 10 -
6
M revealed this isomer to be 
equipotent to dl-propranolol 5 X l0-
6M in exhibiting ventricular 
antiarrhythmic activity during acute myocardial ischemia. 
[BJ 'Membrane stabilizing activity' and ventricular fibrillation 
The beta-adrenoceptor antagonising activity of d(+) isomer of 
propranolol is approximately 50 times less than that of the 1(-) isomer 
of propranolol, while the d ( +) analogue possesses primarily 'membrane 
stabilizing activity' (Barrett and Cullum, 1968). Iansmi th and 
co-workers 
-6 
( 1983) have rece11tly shown that at 10 M, dl propranolol and 
d(+) propranolol both exhibit 'membrane stabilizing activity'. The 
4-6 
equivalent effects of dl and the d(+) analogue of propranolol and of high 
concentrations of metoprolol on the ventricular fibrillation threshold 
can therefore best be explained by their common property 
'membrane-stabilizing activity'. In agreement with this concept, 
atenolol which was without effect on the ischemia-induced fall in the 
ventricular fibrillation threshold lacks 'membrane-stabilizing activity'. 
[CJ Beta adrenergic receptor and ventricular fibrillation 
The beta-adrenergic receptor, as judged by the effects of 
beta-adrenoceptor antagonist agents, does not appear to play a role in 
the genesis of ventricular fibrillation during acute myocardial 
ischemia. Support for this proposal stems from the finding that 
beta-adrenoceptor antagonist agents, in concentrations evoking 
beta-receptor antagonism, do not prevent spontaneous ventricular 
fibrillation during acute myocardial ischemia in the cat (Corr et al, 
1978) and in the pig (Muller, 1981). Moreover, in concentrations higher 
than that required to achieve beta-receptor antagonism, only certain 
beta-antagonists metoprolol but not sotalol prevent ventricular 
fibrillation in the pig (Muller, 1981). In the dog, beta-adrenoceptor 
antagonists, in general, prevent the occurrence of spontaneous 
ventricular fibrillation (Khan et al, 1972; Pearle et al, 1978; Menken 
et al, 1979) or attenuate the fall in ventricular fibrillation threshold 
(Anderson et al, 1983). However, the mechanism of the ventricular 
antiarrhythmic activity has been attributed to several factors: (i) 
beta-adrenoceptor antagonism (Khan et al, 1972; Andersen et al, 1983); 
(ii) 'membrane stabilizing activity' (Sivam and Seth, 1978); (iii) 
prolongation of the action potential duration (Kaufman and Aramendia, 
1968). The prevailing experimental evidence suggests that the 
beta-adrenoceptor does not play a role in the genesis of ventricular 
4-7 
fibrillation during acute myocardial ischemia in the rat, pig and cat 
models. In contrast, in the dog, there is evidence linking the 
beta-adrenoceptor to the genesis of ventricular fibrillation during acute 
myocardial ischemia. This disparate effect of beta-adrenoceptor 
antagonist agents on ventricular antiarrhythrnic activity may reflect 
species difference, there being a higher number of beta-adrenergic 
receptors in . the canine myocardium. 
Beta-adrenoceptor antagonist agents in concentrations producing 
beta-receptor antagonism decrease the incidence of ventricular 
extrasystoles and/or ventricular tachycardia during acute myocardial 
ischernia in the cat (Corr et al, 1978) and pig models (Muller et al, 
1981); the ability of atenolol to exhibit ventricular antiarrhythrnic 
activity during the early phase of acute myocardial ischemia plus 
adrenergic stimulation in the rat probably reflects a similar potential. 
The beta-adrenergic receptor may, therefore, play a role in the genesis 
of ventricular extrasystoles and ventricular tachycardia during acute 
myocardial ischemia. 
[DJ Beta adrenergic receptor and cyclic AMP accumulation 
The beta -adrenergic receptor does not appear to be responsible 
for the accumulation of cyclic AMP in the ischemic myocardium. This 
proposal is based on (i) the failure of extremely high concentrations of 
atenolol to inhibit the rise of cyclic AMP in the ischemic myocardium of 
the rat heart; (ii) the inability of high concentrations of beta 
antagonists, metoprolol, sotalol and propranolol to prevent the 
accumulation of cyclic AMP in the ischernic myocardium of the pig heart 
{Muller, 1981); {iii) the ability of both active 1(-) and relatively 
inactive d { +) isomers of propranolol to prevent accumulation of cyclic 
AMP in the ischemic myocardium of the rat heart. What then 
4-8 
causes the accumulation of cyclic AMP in the ischemic myocardium? The 
answer to this question is unknown but 
0J._ t., 1'11',0..ol a. ,el- al I Wt Cf ) 




[F] Cyclic AMP and ventricular fibrillation 
incriminated include 
in pH inhibiting 
The next question to address is whether the intracellular level 
of cyclic AMP, which is elevated in acute myocardial ischemia, plays a 
role in the genesis of ischemic ventricular fibrillation. Our findings 
with beta-adrenoceptor antagonist agents are in agreement with the 
concept that the intracellular level of cyclic AMP may regulate the 
vulnerability to ventricular fibrillation; thus atenolol neither reduced 
cyclic AMP accumulation nor prevented the fall in the ventricular 
fibrillation threshold, whilst metoprolol and propranolol attenuated both 
the rise in cyclic AMP and also fall in ventricular fibrillation 
threshold. Thus, although the beta-adrenergic receptor may not be 
directly responsible for the rise in cyclic AMP in the ischemic 
myocardium, regulation of the ischemic tissue cyclic AMP level may be 
linked to alteration in vulnerability to ventricular fibrillation with 
beta-adrenoceptor antagonist agents. 
4. CONCLUSIONS 
1. The beta-adrenergic receptor does not appear to play a role in the 
genesis of ventricular fibrillation during acute myocardial ischemia. 
2. The protective effect of beta-adrenoceptor antagonist agents appears 
to be due to a non-specific effect, eg. 'membrane-stabilizing activity' 
rather than due to specific beta-adrenoceptor antagonism. 
3. The beta -adrenergic receptor does not appear to be responsible for 
4-9 
generation of cyclic AMP in the ischemic myocardium. 
4. Changes of intracellular cyclic AMP content in the ischemic 
myocardium can be linked to alteration in the vulnerability to 
ventricular fibrillation produced by beta-adrenoceptor antagonists. 
• 
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Figure 4-1 LOG CONCENTRATION EFFECT CURVES FOR ISOPROTERENOL 
ON HEART RATE IN THE ABSENCE OR PRESENCE OF ATENOLOL 
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EFFECT OF ATENOLOL ON VENTRICULAR FIBRILLATION 
THRESHOLD DURING ACUTE REGIONAL MYOCARDIAL ISCHEMIA 
Coronary artery - Control Atenolol 5 x ,o-5M 
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* p<0·05 
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EFFECT OF ATENOLOL ON VENTRICULAR FIBRILLATION 
THRESHOLD DURING ACUTE REGIONAL MYOCARDIAL ISCHEMIA 
PLUS ADRENERGIC STIMULATION 
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LOG CONCENTRATION EFFECT CURVES FOR ISOPROTERENOL 
ON HEART RATE IN THE ABSENCE OR PRESENCE OF 
METOPROLOL 
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EFFECT OF METOPROLOL ON VENTRICULAR FIBRILLATION 
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EFFECT OF PROPRANOLOL ON VENTRICULAR FIBRILLATION 





. di propranolol 5 x 106 M 
d (+) propranolol 5 x 166M 
. - -- * P<0,001 
* 
• 2 5 10 15 VFT 
Propranolol 
Minutes after coronary artery ligation 
Table 4-1 Effect of beta-adrenoceptor antagonist agents on 
heart rate, total coronary flow rate and ventricular 
fibrillation threshold after coronary artery ligation 
l. Non-ligated heart 
2. Coronary artery 
ligation (CAL) 
p vs l 
3. CAL + atenolol 
5 X 10-5M 
p vs l 
p vs 2 
4. CAL+ atenolol 
l0-4M 
p vs l 




p VS 1 
p vs 2 
6. CAL+ rnetoprolol 
10-4M 
p vs l 
p vs 2 
7. CAL + dl propranolol 
5 X 10-6M 
p vs 1 
p vs 2 
8. CAL + d(+) propranolol 
5 X 10-6M 
p VS 1 
p vs 2 
Number of hearts · = . 5-12 
Values represent Mean+ SEM 
Mean heart rate 
(beats/min) 
243 + 10 
199 + 14 
<0.02 
208 + 7 
<0.05 
NS 
200 + ff 
<0.05 
NS 
192 + 14 -
<0.01 
NS 
129 + 6 -
<0.001 
<0.001 
200 + 8 
<0.05 
NS 






7.8 + 0.5 
3.9 + 0.5 
< 0. 01 
3.7 + 0.5 
< 0. 01 
NS 
3.9 + 0.4 
< 0. 01 
NS 
3.9 + 0.4 
<0. 01 
NS 
3.0 + 0.3 
<0. 01 
NS 
4.1 + 0.3 
<0.01 
NS 




VFT 15' CAL 
(rnA) 
10.0 + 0.3 
2.0 + 0.3 
< 0 .01 
2.6 + 0.5 
< 0. 01 
NS 
3.0 + 0.5 
< 0. 01 
NS 
1.7+0.2 
< 0. 01 
NS 
19.3 + 0.7 
< 0. 01 
<0.01 
9.0 + 2.0 
NS 
< 0.01 
12.8 + 1.3 
NS 






























































































































































































































































































































































































































































































































































Table 4-3 Effect of beta-adrenoceptor antagonist agents on 
tissue cyclic AMP and ventricular fibrillation 
threshold levels 15 minutes after coronary artery 
ligation 
1. Non-ligated heart 
2. Coronary artery 
ligation (CAL) 
p vs 1 
3. CAL+ metoprolol 
10-5M 
p vs 1 
p vs 2 
4. CAL+ metoprolol 
10-4M 
p vs 1 
p vs 2 
5. CAL 
6. CAL+ dl propranolol 
1.6 x 10-5M 
p vs 5 
7. CAL + 1(-) propranolol 
1.6 X 10-5M 
p vs 5 
8. CAL+ d(+) propranolol 
1.6 X 10-5M 
p vs 5 
Number of hearts= 5-12 




0.44 + 0.02 
0.54 + 0.02 
< 0.01 
0.50 + 0.04 
NS 
NS 
0.39 + 0.03 
NS 
<0.001 
0.45 + 0.01 
0.46 + 0.02 
NS 
0.40 + 0.02 
NS 
0.41 + 0.02 -
NS 
(nmol/g) 
0.71 + 0.03 
< 0. 001 
0.61 + 0.05 
<0.01 
NS 
0.38 + 0.01 
<0. 05 
< 0. 001 
0.60 + 0.03 
0.47 + 0.03 
< 0. 01 
0.47 + 0.02 
< 0. 01 
0.44 + 0.02 
< 0. 01 
NB: 5 to 8, data from Lubbe et al (1981) 
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VFT 15' CAL 
(rnA) 
10.0 + 0.3 
2.0 + 0.3 
< 0. 01 
1.7 + 0.2 
< 0. 01 
NS 
19.3 + 0.7 
< o. 01 
< 0. 01 
1.6 + 0.2 
7.7+1.l 
< 0. 01 
7.0 + 1.3 
< 0. 01 
11.5 + 2.8 
< 0. 01 
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CHAPTER 5 
ALPHA-ADRENOCEPTOR ANTAGONIST AGENTS AND VULNERABILITY TO VENTRICULAR 
FIBRILLATION DURING ACUTE REGIONAL MYOCARDIAL ISCHEMIA 
1. PROPOSED ROLE OF ALPHA ADRENERGIC RECEPTOR IN VENTRICULAR 
FIBRILLATION 
Enhanced adrenergic activity has been linked to the development of 
ventricular arrhythmias during acute myocardial ischemia. 







adrenergic receptors. A temporal association 
exists between an increase in alpha1 
receptor number in the ischemic 
myocardium and the occurrence of ventricular arrhythmias during acute 
regional myocardial ischernia in the cat (Sheridan et al, 1980; Corr and 
Crafford, 1982). The alpha1 
adrenergic receptor has therefore been 
implicated in ventricular arrhythmogenesis. 
Alpha
1 
adrenergic stimulation enhances the transsarcolernrnal calcium 
inward current (Bruckner and Scholz, 1980; Scholz 1980) and may cause 
sarcoplasmic reticulum calcium release (Niedergerke and Page, 1981). 
Hence, in ischemic myocardial cells partially depolarized by 
extracellular potassium accumulation, enhanced alpha1 
adrenergic 
stimulation may induce calcium dependent slow response action potentials 
and thereby predispose to reentrant ventricular arrhythmias. If this 
hypothesis is correct then alpha1 
adrenoceptor antagonism should 
inhibit transsarcolemrnal calcium ion influx and thereby prevent slow 
responses and ventricular arrhythmias. Alpha 2 
adrenoceptors are also 
present in tpe myocardium (Guicheney et al, 1978) but their role, if any, 
in ventricular arrhythmogenesis is undefined. The purpose of this study 
5-2 





influences on ventricular arrhythmogenesis. I therefore investigated the 
effect of and adrenoceptor antagonist agents on 
vulnerability to ventricular fibrillation during acute myocardial 
ischemia. 
2. RESULTS 
[AJ Prazosin, Yohimbine and Phentolamine 
Prazosin (alpha
1 






antagonist) prevented the fall in 
the ventricular fibrillation threshold during acute regional myocardial 
ischemia (Figs 5-1, 5-2, 5-3). Complete protection against electrically 
induced fibrillation was evident with prazosin 
-5 
10 M, yohimbine 
and phentolamine More recent experiments illustrate that 
prazosin 1 O - 5M and yohimbine l0-6M attenuate the fall in the 
ventricular fibrillation threshold during acute myocardial ischemia and 
simultaneous adrenergic stimulation (Fig 5-4). 
[BJ Heart rate and coronary flow rate pattern 
Ventricular antiarrhythmic activity occurred despite the 
presence of similar or lower total coronary flow rates than the control 
series subject to coronary artery ligation (Table 5-1). Protection 
against ventricular fibrillation was not associated with a significant 
reduction in heart rate (Table 5-1). 
[CJ Metabolic status 
Prazosin 
-5 




concentrations which exhibited anti-fibrillatory activity, did not 
preserve tissue content of adenosine triphosphate, phosphocreatine or 
glycogen in the ischernic myocardium (Table 5-2). Prazosin and 
-6 
yohirnbine 10 M did not reduce the tissue levels of either lactate or 
cyclic AMP in the ischernic myocardium (Table 5-3). 
[D) Reserpine pre-treatment 
Reserpine 1. 5 mg and 5. 0 mg administered intraperitoneally 48 
and 24 hours respectively prior to sacrifice of the rat depletes 
myocardial stores of catecholamines (Gaudel et al, 1979). Further 
evidence of catecholamine depletion was the failure of tyramine (an agent 
which releases myocardial norepinephrine stores) to increase either the 
heart rate or coronary flow rate. Prior reserpinization did not prevent 
the fall in ventricular fibrillation threshold during acute myocardial 
ischemia (Table 5-4). 
[E) Electrophysiological action of the alpha
1 
adrenoceptor 
antagonist agent, prazosin 
In the isolated superfused guinea-pig papillary muscle, prazosin 
-5 
10 M increased the action potential duration at 90% repolarization but 
did not alter the dV / dt (fast channel conductance) of the transmernbrane 
action potential. Prazosin l0-
6
M produced no alteration of the 
transmembrane action potential (Table 5-5). 
3. DISCUSSION 




antagonist; yohirnbine an alpha
2 
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each completely prevented the enhanced vulnerability to ventricular 
fibrillation during acute regional myocardial ischemia in the absence and 
presence of adrenergic stimulation. These findings complement, in part, 
the recent study of Sheridan and co-workers (1980) in which prazosin and 
phentolamine decreased the incidence of ventricular arrhythmias during 
acute regional myocardial ischemia in the cat; however, a new finding is 
that an alpha
2 
adrenoceptor antagonist agent, yohimbine, displays 
ventricular antiarrhythmic activity. 
[BJ Heart rate, coronary flow and ventricular antiarrhythmic 
activity 




antagonist agents against ventricular fibrillation was not due to 
reduction of heart rate or preservation of total coronary flow rates. 
Ventricular antiarrhythmic activity could occur even in the presence of 
extremely low coronary flow rates during ischemia, thereby arguing 
against the concept that redistribution of coronary flow was responsible 
for protection. It has also been shown in cat model of acute regional 
myocardial ischemia that the' antiarrhythmic effect of alpha1 
antagonist 
agents is unrelated to preservation of or redistribution of coronary flow 
(Sheridan et al, 1980). 
[CJ Metabolic profile and ventricular antiarrhythmic activity 
Ventricular antiarrhythmic activity was not associated with 
preservation of energy status in the ischemic myocardium, thereby 
excluding a metabolic factor in the mechanism of protection. 
Furthermore, ventricular antiarrhythmic activity was not dependent on 
reduction of the cyclic AMP level in the ischemic myocardium. Alteration 
5-5 
i n the vulnerability to ventricular fibrillation may therefore occur 
independently of change in cyclic AMP content. Thus although cyclic AMP 
may be linked to ventricular fibrillation in certain situations, it is 
not the only factor involved in the genesis of ventricular fibrillation 
nor the final messenger of ventricular fibrillation. 
[D J Alpha1 
and alpha 2 
adrenergic receptor mediated 
influences and ventricular fibrillation 
Do both alpha1 
and adrenergic receptor mediated 
influences play a role in the genesis of ventricular fibrillation during 




receptor is questioned on the basis of the following evidence: 






myocardial receptors are located post-synaptically, 
their activation increases transsarcolemmal calcium ion influx and 
possibly also releases calcium from intracellular organelles. Alpha1 
receptor antagonism therefore inhibits transsarcolemmal calcium influx -
such an effect may account for ventricular antiarrhythmic activity. 
myocardial receptors are considered to be located 
presynaptically where they mediate feedback inhibition of noradrenaline 
release theoretically decreasing the transsarcolemmal calcium ion 
influx. receptor antagonism therefore increases 
transsarcolemmal calcium influx - such an effect should evoke ventricular 
arrhythmias rather than induce suppression. The ventricular 
antiarrhythmic effect of both alpha1 
and alpha
2 
antagonist agents is 
therefore difficult to reconcile on the basis of a specific receptor 
mediated event because of the disparate effect of alpha1 
and alpha
2 
receptor mediated influences on calcium fluxes. 
5-6 
Recent evidence that in vascular smooth muscle, 
adrenoceptors are also located post-synaptically and enhance 
transsarcolernrnal calcium ion influx (Timmermans and Van Zwieten, 1982) 
may explain a unitary mechanism of protection for alpha2 
antagonist 
agents and antagonist agents, viz. inhibition of 
transsarcolernrnal calcium ion influx. However, myocardial post-synaptic 
alpha receptors regulating the transsarcolernrnal calcium inward current 
2 ~ 
have, as yet, not been characterized. The anatomical distribution of 
myocardial and alpha 2 
adrenoceptors and their role in 
regulating extracellular and intracellular calcium ion movement needs to 
be clarified in order to understand more fully the ventricular 





(ii) Specificity of concentrations exhibiting ventricular 
antiarrhythrnic activity 
First, the protective concentration of prazosin 
-5 
(10 M) is at 
least 1000-fold higher than the reported dissociation constant of 
alpha
1 
adrenergic receptor in the rat myocardium, 10-lOM (Skomedal et 
al, 1981), whilst the protective concentration of yohirnbine (l0-
6M) is 
at least a 1000-fold higher than the initial dissociation constant of 
alpha
2 
receptor, 10-lOM (Guicheney et al, 1978) and 100-fold higher 
than the final dissociation constant of the alpha 2 
receptor in the rat 
myocardium, l0-
8
M (Guicheney et al, 1978). Secondly, the protective 
concentration of prazosin, an alpha1 
antagonist, approximates that of 
yohirnbine, an alpha 2 
antagonist, thus decreasing the likelihood of a 





receptor mediated influences play a major role in 
the genesis of ventricular fibrillation then myocardial catecholamine 
depletion should prevent the enhanced vulnerability to ventricular 
5-7 
fibrillation. However, myocardial catecholamine depletion by reserpine 
pre-treatment did not prevent the enhanced vulnerability to _ventricular 
fibrillation induced by acute myocardial ischemia. Fourthly, alpha 
adrenergic stimulation lengthens the action potential duration, an effect 
reversed by alpha -adrenoceptor antagonism ( Rosen et al, 19 77) • In this 
study the ventricular antiarrhythmic effect of prazosin was associated 
with prolongation and not shortening of the action potential duration. 
Fifthly, the concentration of phentolamine which protects against 
ventricular fibrillation decreases the automaticity and membrane 
responsiveness and increases action potential duration and effective 
refractory period in canine Purkinje fibres (Rosen et al, 1971). 
The findings presented in the rat suggest that the protective 
effect of. alpha antagonist agents is unlikely to be due to specific 
alpha
1 
or alpha 2 
receptor antagonism but rather due to a non-specific 
effect, viz. 'membrane-stabilizing activity' or prolongation of action 
potential duration. Preliminary work in the dog model of acute regional 
myocardial ischemia suggests that the alpha adrenergic receptor does not 
play a role in the genesis of ventricular arrhythmias ( Stewart et al, 
1980). In contrast, in the cat the alpha1 
adrenoceptor has been linked 
to ventricular arrhythmogenesis however, the role of the alpha 2 
adrenoceptor has not been evaluated (Corr and Crafford, 1982). The 
ventricular antiarrhythmic effect of alpha1 
antagonist agents in the 
cat has been linked to reduction in cellular calcium concentration 
( Sharma et al, 198.3) • 




receptors in the genesis of ventricular fibrillation is unclear at 
present. Investigation of the anatomical distribution of myocardial 
alpha1 and alpha 2 
receptors, their regulation of extracellular and 
intracellular calcium ion movement and their relation to ventricular 







adrenoceptor antagonist agents completely 
prevent the enhanced vulnerability to ventricular fibrillation during 
acute myocardial ischemia. 
2. The ventricular antiarrhythmic activity is not due to reduction of 
heart rate, maintenance of coronary flow rates, preservation of metabolic 
status or reduction of cyclic AMP content in the ischemic myocardium. 
3 . The ventricular antiarrhythmic activity of alpha antagonist agents 
appear to be due to a non-specific effect, viz. 'membrane-stabilizing 
activity' or prolongation of the action potential duration. 
3. The alpha adrenergic receptor does not appear to be implicated in the 
genesis of ventricular fibrillation during acute myocardial ischemia -
however, further investigation is required before one can exclude a role 
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EFFECT OF PRAZOSIN ON VENTRICULAR FIBRILLATION 
THRESHOLD DURING ACUTE REGIONAL MYOCARDIAL ISCHEMIA 
Coronary artery 
i ligation 
.. k .. ······ * . ... 
_ Control 
- - • Prazos1n 10-6M 
- Prazosin 5x10-6M 
••••• Prazosin 10-SM * p< 0.05 
**P< 0.01 

















EFFECT OF YOHIMBINE ON VENTRICULAR FIBRILLATION 





~~~ ............ ]** T 
- Control 
- -· Yohimbine 10-7M 
- Yohimbine 5x10-7M 
• • • • • • Yohimbine 10-6M 
* p <0.05 
** p< 0,01 
' ······ ' ············-!** 
' •••••••••••••••• "L..* **T * ' * ·-.~'!: ••••••••••••••••• o 
' ' ~ 
' ' ' ' 
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2 5 10 15 
Minutes after coronary artery ligation 
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Figure 5-3 EFFECT OF PHENTOLAMINE ON VENTRICULAR FIBRILLATION 












**~ ** ** 
- Control 
- - Phentolamine 5x166M 


















EFFECT OF ALPHA-ADRENOCEPTOR ANTAGONIST AGENTS ON 
VENTRICULAR FIBRILLATION THRESHOLD DURING ACUTE 
REGIONAL MYOCARDIAL ISCHEMIA PLUS ADRENERGIC 
STIMULATION 
Preligation ~ Coronary artery ligation ~ 
+ 














p vs 1 
3. Prazosin 
p vs 1 
4. Yohimbine 
p vs 1 
5. Yohimbine 
p vs 1 
6. Yohimbine 
p vs 1 
10-5M 
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Effect of alpha-1 and alpha-2 adrenoceptor antagonist 
agents on heart rate, total coronary flow rate before 
and after coronary artery ligation 
Non-ligated heart Coronary artery ligation 
CF HR CF HR 
(ml/min) (beats/min) (ml/min) (beats/min) 
7.8 243 3.9 199 
+0.5 +10 +0.5 +14 
8.4 266 2.0 156 
+0.4 +6 +0.1 +7 
NS NS < 0. 05 < 0. 05 
5 x 10-6M 8.3 266 2.8 174 
+0.5 +13 +0.2 +8 
NS NS NS NS 
10-6M 9.4 268 3.2 179 
+0.4 +7 +0.2 +10 
NS NS NS NS 
5 X 10-7M 7.6 252 2.8 197 
+0.4 +11 +0.3 +18 
NS NS NS NS 
10-7M 9.4 287 3.6 221 
+0.3 +8 +0.3 +15 
NS NS NS NS 
7. Phentolamine 5 x 10-6M 7.9 274 3.3 195 
+0.2 +17 +0.3 +4 
p vs 1 
- -
NS NS NS NS 








































































































































































































































































































































































































































































































































































































































































































Effect of alpha-1 and alpha-2 adrenoceptor antagonist 
agents on tissue cyclic AMP and ventricular 
fibrillation threshold levels 15 minutes after 





VFT 15' CAL 
(mA) 
Non-ligated heart 0.44 + 0.02 
10. 0 + 0.3 
Coronary artery 
ligation (CAL) 
p vs l 
CAL + prazosin 10-5M 
p vs l 
p vs 2 
CAL+ yohimbine 10-6M 
p vs l 
p vs 2 
* p < 0. 01 
Number of hearts= 6-12 
Values represent Mean+ SEM 
0.54 + 0.02 0.71 + 0.03 2.0 + 0.3 
<O. 01 <0.001 < o. 01 
0.64 + 0.05 0.72+0.02 14.9 + 1.4* 
< 0. 01 <0.001 NS 
< 0.05 NS <0.01 
0.61 + 0.02 0.64 + 0.03 10.5 + 1.5* 
<0.01 < 0. 001 NS 
<0.05 NS <0.01 
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Table 5-4 Effect of reserpine pre-treatment on ventricular 
fibrillation threshold level 15 min after coronary · 
artery ligation 
1 . Coronary artery ligation (CAL) 
(n = 8) 
2. Reserpine pre-treatment+ CAL 
(n = 7 ) 
p VS 1 
Values represent Mean+ SEM 
VFT preligation 
(mA) 
8.0 + 0.4 
7.6 + 0 .3 
VFT 15' CAL 
(mA) 
1.9 + 0.3 




p vs 1 
3. Control 
4. Prazosin 
p vs 3 
(n = 3) 
10-6M 
(n = 4) 
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Electrophysiologic action of prazosin on guinea-pig 
ventricular myocardium 
(n = 3) 
Action potential duration 
90% repolarization 
(msec) 
158 + 4 
159 + 7 
NS 
151 + 3 -
dV/dt 
(v/sec) 
250 + 35 
250 + 35 
NS 
290 + 14 
10-5M (n = 4) 181 + 4 310 + 22 
< o. 02 NS 
Values represent Mean+ SEM, 40 min after addition of prazo
sin 
CHAPTER 6 
CALCIUM-ANTAGONIST PROCEDURES AND VULNERABILITY TO VENTRICULAR 
FIBRILLATION DURING ACUTE REGIONAL MYOCARDIAL ISCHEMIA 
1. PROPOSED ROLE OF CALCIUM IONS IN VENTRICULAR FIBRILLATION 
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The development of acute myocardial ischemia is associated with a 
rapid increase of extracellular potassium (Harris, 1954; Hirche et al , 
1980), and an accumulation of cyclic AMP in the ischemic myocardium 
(Podzuweit et al, 1978). In this environment, elevated levels of cyclic 
AMP may promote formation of slow response action potentials (Reuter, 
1974; Gettes, 1975; Vogel and Sperelakis, 1981). Recently an increase 
in alpha
1 
adrenergic receptor number (Corr et al, 1981a) has been 
demonstrated in the ischemic myocardium; enhanced alpha1 
receptor 
stimulation may theoretically also induce formation of slow response 
action potentials (Bruckner and Scholz, 1980; Scholz, 1980). 
Current electrophysiological evidence indicates that the calcium 
dependent slow response action potential is one possible mechanism which 
may be responsible for reentry and hence generation of early ventricular 
arrhythmias during acute myocardial ischemia (Cranefield, 1975; Wit and 
Bigger, 1975). 
If this hypothesis relating to the electrophysiological mechanism of 
early ventricular arrhythmias is correct, then calcium antagonist 
procedures which inhibit transsarcolemmal calcium inward current 
(Fleckenstein, 1971) should also antagonise calcium dependent slow 
response action potentials and thereby protect against early ventricular 
arrhythmias. 
The present investigation was, therefore, designed to study the 
6-2 
effect of calcium channel antagonist agents and re
duction of 
extracellular calcium on the vulnerability to ventricular fibrillation 
during acute regional myocardial ischemia. 
2. RESULTS 
[A] Verapamil 
Verapamil increased the coronary flow rates, verapamil 1. 5 x 
9.1 + 1.1 to 14.9 + 1.0 (p<0.005), 
-8 
6 X 10 M, 9 . 2 + 0 . 5 to 
12.2 + 0.7 ml/min (p <0.005) respectively and decreased the heart rate, 
verapamil 1. 5 x l0-
7
M, 226 + 11 to 195 + 4 (p< 0.05), 
-8 
6 x 10 M, 224 
+ 2 to 196 + 1 beats/min (p< 0.001) respectively. 
conduction block occurred when concentrations above 
Atrioventricular 
-7 
1.5 x 10 M were 
used. 
After coronary artery ligation the total ( ischemic and 
non-ischemic) coronary flow rates fell, verapamil 1.5 
-7 
X 10 M, 9.3 + 
1. 3 (p< 0.0001); 6 X 
-8 
10 M, 7. 5 + 0 . 5 ml/min (p < 0. 001) respectively, 
but were elevated in comparison to total coronary flow rates ( 3. 9 + 
0.5 ml/min) of control coronary artery ligated hearts (Table 6-1). 
Verapamil 1.5 X 
-7 
10 M did not elevate the ventricular 
fibrillation threshold in the non-ligated heart but maintained higher 
ventricular fibrillation threshold values during the phase of acute 
regional myocardial ischemia (Fig 6-1). In a separate series of hearts 
paced at a heart rate ( 230 beats/min) similar to the control series, 
verapamil 1.5 X 10-
7 
M maintained higher ventricular fibrillation 
threshold levels during acute regional myocardial ischemia, thus 
excluding slow heart rat'e as the factor mediating protection against 
ventricular fibrillation (Fig 6-1). Investigation with d(+) and 1(-) 
optimal isomers of verapamil 1.5 X 
-7 
10 M (both series paced at 
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230 beats/min) showed that d(+) verapamil 1.5 x l0-
7
M was as effective 
as 1(-) verapamil 1.5 x l0-
7
M in attenuating the fall in the 
ventricular fibrillation threshold during myocardial ischemia (Fig 6-2). 
dl verapamil 1. 5 X attenuated the fall in the 
ventricular fibrillation threshold during acute myocardial ischemia with 
concomitant adrenaline 5 x l0-
7
M stimulation (Fig 6-6). Investigation 
with the optical isomers of verapamil showed that 1(-) verapamil but not 
d(+) verapamil 1.5 x l0-
7
M attenuated the fall in the ventricular 
fibrillation threshold during 





10 M produced 




dependent increase in the coronary flow rates prior to ligation and 
preserved coronary flow rates during acute myocardial ischemia 
(Table 6-1). 
-6 
Nifedipine 1 x 10 M was the highest concentration which 
could be used without production of spontaneous atrioventricular 
dissociation. 
In non-ligated hearts, nifedipine 1 x l0-
6M elevated the 
ventricular fibrillation threshold 10.8 + 1.3 to 16.5 + 2.2 rnA 
(p <0.05). 
-6 
Nifedipine 1 x 10 M was associated with higher ventricular 
fibrillation threshold values throughout the 15 min · period of acute 




and 1 x 10 M this was not evident (Fig 6-3). 
-6 
Nifedipine 1 x 10 M also attenuated the fall in ventricular 
fibrillation threshold during acute myocardial ischemia plus adrenaline 5 
x l0-
7
M stimulation (Fig 6-6). 
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[CJ Diltiazem 
Diltiazem 5 x 
-6 
10 M, 5 X 
-7 
10 M and l x 
-7 
10 M increased 
coronary flow rates in similar fashion to verapamil and nifedipine 
-6 
(Table 6-1). At concentrations higher than l x 10 M complete 
-7 -6 
atrioventricular dissociation occurred. Diltiazem 10 M to 5 x 10 M 
did not increase the ventricular fibrillation threshold levels in 
non-ligated hearts at all concentrations tested. 
The series of hearts perfused with dil tiazem 5 x l O -
6
M and 
paced at a heart rate of 230 beats/min exhibited a similar trend to the 
verapamil 1.5 x l0-
7
M and nifedipine 
-6 
l x 10 M series in being able 
to maintain higher ventricular fibrillation threshold values during the 
15 min period of acute myocardial ischemia (Fig 6-4). Unlike nifedipine, 
dil tiazem in lower concentrations, 
-7 -7 
5 x 10 M and l x 10 M, displayed 
a trend towards higher ventricular fibrillation threshold values in the 
first 10 min following coronary artery ligation but at 15 min this was 
not evident (Fig 6-4). 
During acute myocardial ischemia with adrenaline 5 x l0-
7
M 
stimulation, diltiazem 5 
-6 
x 10 M partially prevented the fall in the 
ventricular fibrillation threshold (Fig 6-6). 
[DJ 
2+ . 
Reduction in perfusate Ca concentration 
Reduction in the perfusate calcium ion concentration from 2.5 mM 
to l. 0 mM was not associated with preservation of coronary flow rate or 
reduction in heart rate during acute myocardial ischemia (Table 6-1). 
Reduction in the extracellular calcium ion concentration was, however, 
associated with higher ventricular fibrillation threshold levels during 
acute myocardial ischemia in the absence or presence of adrenaline 5 x 
l0-
7
M stimulation (Figs 6-5, 6-8). 
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[E) High energy phosphates 
The tissue measurements of adenosine triphosphate and 
phosphocreatine in both the non-ischemic and ischemic myocardium in the 
control series and in hearts subjected to calcium-antagonist procedures 
are shown in Table 6-2. 
Calcium channel antagonist agents, in general, maintained higher 
ATP levels in the ischemic myocardium. However, reduction in perfusate 
2+ 
ca concentration from 2.5 mM to 1.0 mM was not associated with 
preservation of ATP in the ischemic myocardium. Both decreased and 
increased vulnerability to ventricular fibrillation ( compare nifedipine 
series) were associated with preservation of ATP in the ischemic 
myocardium. Moreover protection against ventricular fibrillation could 
occur in the absence of preservation of ATP in the ischemic myocardium, 
viz verapamil 1. 5 x 10-
7 
M (paced series) and reduction in perfusate 







agents but not a lowered 
displayed a trend towards 
preservation of phosphocreatine levels in the ischemic myocardium. 
However no association was evident between myocardial phosphocreatine 
levels and vulnerability to ventricular fibrillation. 
[F] Cyclic AMP (Table 6-3) 
In the control non-ligated rat heart the cyclic AMP content was 
0.44 + 0.02 nmol/g fresh weight. In the control coronary artery ligated 
rat heart, the cyclic AMP content in the non-ischemic myocardium was 0.54 
+ 0. 02 and in the ischemic myocardium O. 71 .:!:. 0. 03 nmol/g fresh weight 
respectively. The cyclic AMP level in the non-ischemic myocardium was 
elevated in comparison to the level in the non-ligated heart (p < 0. 01). 
In addition, there was an accumulation of cyclic AMP in the ischemic 
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myocardium relative to the non-ischemic myocardium (p( 0.001). This 
increase in cyclic AMP in the ischemic myocardium has been considered to 
play a major role in ventricular arrhythmogenesis. 
Calcium channel antagonist agents reduced cyclic AMP levels in 
the ischemic myocardium, nifedipine l0-
6M, 0.56 + 0.02 (p( 0.02), 
diltiazem 5 X l0-
7M, 0.53 + 0.04 (p( 0.01) vs control 0. 71 + 0.03 
nmol/g fresh weight. Nifedipine 5 X 10-?M reversed the cyclic AMP 
content in the ischemic zone to the level found in the control 
non-ligated heart. Reduction in perfusate calcium concentration 
decreased cyclic AMP levels in both the non-ischemic and ischemic 
myocardium to values comparable to that found in the control non-ligated 
rat heart. 
Lower cyclic AMP levels in the ischemic myocardium were 
associated in some series with protection and in other series with no 
protection against ventricular fibrillation. Although there was an 
absolute reduction in the cyclic AMP content in the ischemic zone in all 
series subjected calcium antagonist procedures, the cyclic AMP levels in 
these zones were always higher than the -values present in the 
non-ischemic myocardium. Thus a relative accumulation of cyclic AMP 
still occurred in the ischemic zone. 
3. DISCUSSION 
Verapamil 1.5 x l0-
7M, nifedipine l0-
6M, diltiazem 5 x l0-
6M 
2+ 
and a reduction in the extracellular Ca ion concentration attenuated 
the fall in the ventricular fibrillation threshold during acute 
myocardial ischemia in the absence and presence of adrenergic 
stimulation. Recent studies in the dog (Brooks et al, 1980; Clusin et 
al, 1982), rat ('Fagbemi and Parratt, 1981) and pig (Muller et al, 1984) 
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complement our findings that calcium channel antagonist agents exhibit 
ventricular antiarrhythmic activity during acute myocardial ischemia. 
The exact mechanism whereby protection against ventricular fibrillation 
occurs appears complex in view of the heterogeneity of effects produced 
by calcium antagonist procedures, viz. ( i) slowing of the heart rate; 
(ii) coronary artery vasodilation; (iii) preservation of myocardial high 
energy phosphate content; (iv) reduction in tissue cyclic AMP content; 
(v) inhibition of transsarcolernrnal calcium influx and (vi) non-specific 
effect . 
[A ] Heart rate 
The ventricular antiarrhythmic effect of calcium antagonist 
procedures occurred independently of the heart rate. First, reduction in 
perfusate calcium concentration attenuated the fall in the ventricular 
fibrillation thre'Shold despite no alteration in the heart rate. 
Secondly, hearts perfused with verapamil and paced at a heart rate 
similar to the control series maintained higher ventricular fibrillation 
threshold values during acute myocardial ischemia. 
[B] Coronary artery vasodilation 
Maintenance of higher coronary flow rates or redistribution of 
coronary flow via coronary artery vasodilation is one possible mechanism 
whereby calcium antagonist procedures may exhibit ventricular 
antiarrhythmic activity (Ross and Jorgensen, 1967; Haas and Hartfeldes, 
1962). 
However, preservation of total coronary flow rates during acute 
myocardial ischemia was associated in some series with protection whilst 
in other series with lack of protection against ventricular 
fibrillation. Moreover reduction in perfusate calcium concentration 
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exhibited antifibrillatory activity despite no alteration in total 
coronary flow rates. Since intramyocardial coronary flow redistribution 
was not measured, this factor cannot be excluded in the mechanism of 
protection. However, the following arguments suggest that this was 
unlikely to be the factor mediating protection. First, a lowered 
extracellular calcium concentration exhibited ventricular antiarrhythmic 
activity but did not alter total coronary flow rates; reduction in 
extracellular calcium concentration has not been shown to cause 
redistribution of coronary flow (Clusin et al, 1982). Secondly, in two 
other series, the antifibrillatory effect of verapamil and diltiazem 
could not be ascribed to coronary artery vasodilation or redistribution 
of coronary flow (Sherman et al, 1981; Clusin et al, 1982). 
[CJ High energy phosphates 
Procedures which inhibit cardiac metabolism may preserve high 
energy phosphate content (Weber, 1959). Preservation of energy status 
may maintain cell membrane integrity and also prevent the decrease in 
action potential duration; two factors which may account for ventricular 
antiarrhythmic action. 
Calcium channel antagonist agents demonstrated a trend towards 
preservation of ATP in the ischemic myocardium. However, high ATP levels 
were associated with both decreased and increased vulnerability to 
ventricular fibrillation ( compare nifedipine series) • Furthermore, 
protection against ventricular fibrillation could occur in the absence of 
preservation of ATP in the ischemic myocardium (reduced perfusate calcium 
-7 
series and paced verapamil 1. 5 x 10 M series). Tissue levels of PCR 
did not correlate with antifibrillatory activity. Thus attenuation of 
the fall in the ventricular fibrillation threshold occurred independently 
of preservation of energy status. 
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[DJ Cyclic AMP 
Podzuweit et al (1976) proposed that accumulation of cyclic AMP 
in the ischemic myocardium may play a major role in the genesis of 
ventricular fibrillation. The present study demonstrates that all 
calcium antagonist procedures reduced levels of cyclic AMP in both the 
non-ischemic and ischemic myocardium. Reduced cyclic AMP content in the 
ischemic myocardium was associated with both protection and lack of 
protection against electrically induced ventricular fibrillation. 
If cyclic AMP is held to be an arrhythmogenic agent, why are 
reduced levels in the ischemic myocardium not associated with 
protection? The exact reason for this complex· finding is unclear, but 
there are two possible explanations: 
1. Although calcium antagonist procedures reduced the cyclic AMP content 





was significantly higher than that found in the 
in all series. Specifically, nifedipine 5 x 10 -
7 
M 
reduced the cyclic AMP level in ischemic zone to normal levels, but was 
not associated with protection. However, this cyclic AMP level in the 
ischemic zone was still elevated relative to the non-ischemic 
myocardium. Thus the relative accumulation of cyclic AMP in the ischemic 
myocardium rather than the absolute level in the ischemic zone may be of 
importance in the genesis of ventricular fibrillation. 
2. The alternative possibility is that cyclic AMP does not play a role 
in the genesis of ventricular fibrillation during acute myocardial 
ischemia. 
[EJ Calcium channel antagonist agents - alpha-adrenoceptor 
interaction 





adrenoceptors (Nayler et al, 1982). Hence it has been suggested 
that the ventricular antiarrhythmic activity of verapamil may not be due 
to inhibition of the transsarcolernrnal calcium inward current but rather 





adrenergic receptors (Motulsky et al, 1983); 
hence it can be termed a relatively 'pure calcium antagonist'. That 
nifedipine antagonised the enhanced vulnerability to ventricular 
fibrillation during acute myocardial ischemia is strong, albeit indirect, 
evidence that the protective effect is due to inhibition of 





[F] Optical isomers of verapamil 
To further define the mechanism of protection of calcium 
antagonists and to analyse the role of the transsarcolernrnal calcium 
current in ventricular arrhythmogenesis, investigation was undertaken 
with the d(+) and 1(-) isomers of veraparnil. Electrophysiological 
studies in the superfused guinea-pig papillary muscle showed that 
blockade of the slow channel calcium current was achieved by 1(-) but not 
d ( +) veraparnil; both isomers did not affect the fast sodium channel. 
Recent evidence suggests that qualitatively both 1 (·-) and d ( +) verapamil 
block the slow calcium channel; however quantitatively 1(-) verapamil is 
more potent than d ( +) verapamil. Both isomers, reputedly, only inhibit 
the fast sodium channel when used in concentrations above 3 x 10 -
6
M 
(Gloor and Urthaler, 1983). 
In the isolated rat heart, both 1 (-) and d ( +) verapamil 1. 5 x 
-7 
10 M partly attenuated the fall in the ventricular fibrillation 
threshold during acute myocardial ischernia. During acute myocardial 
ischemia with · concomitant adrenergic stimulation, 1(-) but not 
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d(+) verapamil attenuated the enhanced vulnerability to
 ventricular 
fibrillation. The antifibrillatory effect of ver
apamil appears specific 
to the calcium channel during the setting of myocardial 
ischemia and 
adrenergic stimulation. 
[G J Reduction in extracellular calcium ion concentration 
More direct evidence that the transsarcolemmal calcium i
nward 
current plays a role in ventricular arrhythmogenesis st
ems from the 
finding that a reduction in perfusate calcium concentration 
decreased the 
vulnerability to ventricular fibrillation during 
acute myocardial 
ischemia. Further support for an arrhythmogenic role of c
alcium arise s 
from the data of Clusin and co-workers ( 1982 ) t hat reduc
tion in serum 
ionized ca l cium by infusion of Na citrate mimics the effec
t of diltiazem 
i n prolonging the latency period to ventricular fibrillatio
n in the dog 
model of global left ventricular ischemia. 
The findings presented in this chapter indicate that
 t he 
transsarcolemmal calcium current plays a role in the
 genesis of 
ventricular fibrillation dur i ng acute myocardia l ischernia. T
hat calci~, 
antagonist procedures only partia l l y prevent the fal l i n th
e ventricul a r 
fibrillation threshold suggest that the transsarcolernrna l c
alcium current 




l. Calcium channel antagonist agents and a reductio
n in the 
extracellular calcium concentration attenuated the fall i
n ventricular 
fibrillation threshold during acute myocardial ischemia 
both in the 
absence and presence of adrenergic stimulation. 
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2. Protection was not due to maintenance of total coronary flow, 
reduction in heart rate, preservation of energy status or reduction in 
cyclic AMP content. 
3. Redistribution of coronary flow from non-ischemic to ischemic 
myocardium, although unlikely, could not be excluded in the mechanism of 
protection. 
4. The transsarcolemrnal calcium inward current appears to play a role in 
the genesis of ventricular fibrillation during acute myocardial ischemia. 
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Figure 6-1 EFFECT OF VERAPAMIL ON VENTRICULAR FIBRILLATION 
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EFFECT OF NIFEDIPINE ON VENTRICULAR FIBRILLATION 
THRESHOLD DURING ACUTE REGIONAL MYOCARDIAL ISCHEMIA 
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1 x 10-6 M 
-- 5 X 10-7M 
1x10- 1 M 
* p<0.02 
** p <0.001 
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Drug n: 6 
-
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VFT 
Nifedipine Minutes after ligation 
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Figure 6-4 EFFECT OF DILTIAZEM ON VENTRICULAR FIBRILLAT
ION 
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• • •• • 1 X 10-7 M 
* p < 0.05 
** p < 0,02 
















EFFECT OF REDUCTION OF EXTRACELLULAR CALCIUM 
CONCENTRATION ON VENTRICULAR FIBRILLATION THRESHOLD 
DURING ACUTE REGIONAL MYOCARDIAL ISCHEMIA 
Coronary artery - Ca
2+2.5mM 
~ ligation - - Ca
2 + 1,25 mM 
- Ca2 + 1.0 mM 
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EFFECT OF CALCIUM ANTAGONIST AGENTS ON VENTRICULAR 
FIBRILLATION THRESHOLD DURING ACUTE REGIONAL 
MYOCARDIAL ISCHEMIA PLUS ADRENERGIC STIMULATION 
INFUSION OF ADRENALINE 5 x 10 ..-M THROUGHOUT 
*P< 0.05 
* * P< 0.01 
* p< 0.002 
D Control 
[] Oiltiazem 5x10-6M 
• Nifedipine 1 x 10-6 M 
ii Verapamil 1,sx10-1M 
o, ...... _..__...i.--.---
Pre- 2 5 15 












EFFECT OF d(+) AND 1(-) VERAPAMIL ON VENTRICULAR 
FIBRILLATION THRESHOLD DURING ACUTE REGIONAL 
MYOCARDIAL ISCHEMIA PLUS ADRENERGIC STIMULATION 
,, 
INFUSION OF ADRENALINE 5 x 10-
7M THROUGHOUT 
D Control 
: ~ ~:;:~::;: J1-s x10-7M 
* P< 0·001 
2 5 10 15 













EFFECT OF REDUCTION OF EXTRACELLULAR CALCIUM ION 
CONCENTRATION ON VENTRICULAR FIBRILLATION THRESHOLD 
DURING ACUTE REGIONAL MYOCARDIAL ISCHEMIA PLUS 
ADRENERGIC STIMULATION 
INFUSION OF ADRENALINE 5 x 10-7 M 
* c::::J Ca2+ 2·5 mM 
- ca2+ 1·0 mM 
* D < 0·02 
5 10 15 
Minutes after coronary artery ligation 
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Table 6-1 Effect of calcium channel antagonist agents and 
reduction in extracellular calcium on heart rate, 
total coronary flow rate and ventricular fibrillation 




Coronary artery ligation 
(CAL) 
CAL+ Verapamil 
1. 5 X l0-7M 
CAL+ 1(-)verapamil 
1. 5 X 10-7M 
CAL+ nifedipine 
1 X 10-6M 
CAL .+ nifedipine 
5 X 10-7M 
CAL + nifedipine 
1 X 10-7M 
CAL + diltiazem 
5 X 10-6M 
CAL+ diltiazem 
5 X 10-7M 
CAL+ lowered perfusate 
ca2+ (l.OmM instead of 
2.5mM) 
*p < 0. 02 **p < 0. 001 
Number of hearts= 6-12 
Values represent Mean+ SEM 
Mean heart rate 
(beats/min) 
243 + 10 
199 + 14 
250 (paced) 
230 (paced) 
185 + 8 
201 + 8 -
194 + 9 
230 (paced) 
183 + 14 
221 + 7 
p values vs coronary artery ligation 
Mean coronary flow 
(ml/min) 
7.8 + 0.5 
3.9 + 0.5 
9.3 + 1. 3** -
8.0 + 0.5** 
9.0 + 0.8** 
NS 
8.0 + 0.4** 
8.0 + 0.7** 
10.l + 0.3** 
P< 0. 02 
7.9 + 0.5** 
4.0 + 0.2 
In addition, p values nifedipine 1 x 10-6M vs nifedipine 5 x 10-7M 
and diltiazem 5 x 10-6M vs diltiazern 5 x 10-7M 
VFT 15' CAL 
(mA) 
10.0 + 0.3 
2.0 + 0.3 
6.7 + 1.8* 
4.9 + 0.8* -
4.7 + 0.9* 
p<0.001 
1.3 + 0.2 
1.8 + 0.4 
4.8 + 0.5** 
p:: 0. 001 
1.9 + 0.6 
4.3 + 0.7* 
Table 6-2 Effect of calcium channel antagonist agents and 
reduction in extracellular calcium on tissue high 
energy phosphate and ventricular fibrillation 
threshold levels 15 minutes after coronary artery 
ligation 
Non-ischemic Ischemic 
Procedure myocardium myocardium 
{pmol/g) {pnol/g) 
ATP PCr ATP PCr 
Coronary artery ligation 3.90 4.49 1. 91 1. 77 
+0.23 +0.61 +0.28 +0.39 
Verapamil 1. 5 X 10-7M 3.19 4.81 2.85 2.87 
paced +0.31 +0.66 +0.45 +0.98 
Veraparnil 1. 5 X 10-7M 5.27** 5.66 4.70*** 3.98** 
unpaced +0.12 +0.37 +0.54 +0.92 
Nifedipine l x 10-6M 3.51 4.28 2.74** 2.13 
+0.05 +0.05 +0.13 +0.21 
Nifedipine 5 x 10-7M 4.36 5.46 2.84* 3.04 
+0.29 +0.69 +0.20 +0.35 
Diltiazem 5 x 10-7M 3.54 4.07 2.39 2.52 
+0.21 +0.16 +0.28 +0.34 
Diltiazem 5 x 10-6M 3.63 3.35 2.37 1.61 
+0.09 +0.10 +0.13 +0.13 
Lowered perfusate ca2+ 3.47 3.99 1. 51 1.03 
{l.OrnM instead of 2. 5rnM) +0.21 +0.24 +0.20 +0.09 
*p < 0. 05 **p < 0. 02 ***p< 0.001 
p value vs coronary artery ligation 




















Table 6-3 Effect of calcium channel antagonist agents and 
reduction in extracellular calcium on tissue cAMP 
and ventricular fibrillation threshold levels 
15 minutes after coronary artery ligation 
Cyclic AMP 
Non-ischemic Ischemic 
Procedure myocardium myocardium 
(nmol/g fresh wt) (nmol/g fresh wt) 
1. Control 0.44 + 0.02 
(non-ligated heart) 
2. Coronary artery 
ligation (CAL) 0.54 + 0.02 <0.001 0.71 + 0.03 
p vs 1 <0.01 < 0. 001 
3. Verapamil l.5xl0-7M 0.39 + 0.03 <0.02 0.55 + 0.05 
unpaced 
p vs 1 NS NS 
p vs 2 <0.001 <0.01 
4. Nifedipine lxl0-6M 0.41 + 0.05 <D. 05 0.56 + 0.02 
p vs 1 NS <0. 01 
p vs 2 <0.01 <0.01 
5. Nifedipine 5xlo-7M 0.32 + 0.03 <0. 02 0.46 + 0.04 
p VS 1 < 0.01 NS 
p vs 2 < 0.001 <0.005 
6. Diltiazem 5xl0-7M 0.42 + 0.03 <0.05 0.53 + 0.04 
p vs 1 NS NS 
p vs 2 <0.01 < 0. 01 
7. Diltiazem 5xlo-6M 0.44 + 0.02 <0.005 0.55 + 0.02 
p vs 1 NS < o. 01 
p vs 2 <0.01 < o. 01 
8. Lowered perfusate 0.36 + 0.03 <0.01 0.46 + 0.02 
ca2+ 
( 1. OmM instead of 
2.5mM) 
p vs 1 NS NS 
p vs 2 <0.001 <0.001 
n = 5 to 12 




10.0 + 0.3 
2.0 + 0.3 
< 0. 01 
4.5 + 0.4 
< 0. 01 
< 0. 01 
4.7 + 0.9 
< 0. 01 
< 0. 02 
1.3 + 0.2 
< 0.01 
NS 
1.9 + 0.6 
< 0. 01 
NS 
4.8 + 0.5 
< o. 01 
< 0. 01 
4.3 + 0.7 
< 0. 01 
< 0. 02 
CHAPTER 7 
FAST CHANNEL BLOCKING AGENTS AND VULNERABILITY TO VENTRICULAR 
FIBRILLATION DURING ACUTE REGIONAL MYOCARDIAL ISCHEMIA 
1. PROPOSED ROLE OF SODIUM IONS IN VENTRICULAR FIBRILLATION 
7-1 
The development of acute myocardial ischemia is associated with 
accumulation of extracellular potassium ion concentration in the ischemic 
myocardium, peak recorded values reaching 16. 3 mM { Hirche et al, 1980). 
This degree of extracellular potassium accumulation has been shown to 
decrease the- resting membrane potential of cardiac cells to values 
approximating -60 mV. It has been presumed that at such resting membrane 
potentials, the fast sodium channel is inactivated and the upstroke of 
the action potential is generated by enhanced calcium inward current 
evoked by adrenergic stimulation. Such action potentials, termed slow 
responses, are considered to be responsible for slow conduction in the 
ischemic myocardium and also the development of early ventricular 
fibrillation. 
However, to date there is no conclusive evidence that the initial 
upstroke of the ischemic action potential is due to the slow inward 
calcium current. Recent evidence shows that at resting membrane 
potentials of -57 mV to -60 mV, the fast sodium channel even though it is 
almost completely inactivated, plays a role in generation of the initial 
upstroke of the action potential {Arita et al, 1983). Such action 
potentials, termed depressed fast responses are associated with 
conduction velocity slow enough to maintain reentrant circuits {Arita et 
al, 1983). Depressed fast responses may therefore be responsible for the 
slow conduction in the ischemic myocardium and also the development of 
early ventricular fibrillation. 
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If this hypothesis is correct then fast channel blocking agents which 
inhibit the transsarcolemmal sodium inward current should inhibit the 
occurrence of depressed fast responses and thereby prevent early 
ventricular fibrillation. I, therefore, investigated the effect of fast 
channel blocking agents, lignocaine and tetrodotoxin, on vulnerability to 





3 x 10 M and 5 x 10 M elevated the ventricular 
fibrillation thr-eshold, reduced heart rate and decreased coronary flow 
rates respectively prior to coronary artery ligation. During acute 
myocardial ischemia lignocaine 3 X 
-5 -5 -5 
10 M to 5 x 10 M but not 10 M 
maintained higher ventricular fibrillation threshold levels than the 
control ·· series subject to coronary artery ligation; in fact complete 
ventricular antiarrhythmic activity was evident (Fig 7-1). Protection 
was associated with heart rates and total coronary flow rates similar to 
that of the control series (Table 7-1); moreover preservation of 
metabolic status in the ischemic myocardium was not evident (Table 7-2). 
However, ventricular antiarrhythmic activity was accompanied with 
reduction in cyclic AMP content in both the non-ischemic and ischemic 
myocardium (Table 7-3). 
[BJ Tetrodotoxin 
Tetrodotoxin 5 x 
-7 -6 
10 M and 3 x 10 M reduced the heart rate 
prior to coronary artery ligation: 296 + 15 to 237 + 11 (p< 0.05); 272 
.:!:. 9 to 206 .:!:_ 7 (p < 0. 05) but did not alter coronary flow rate prior to 
coronary artery ligation: 8.8 + 0.6 to 7.6 + 0.4 (NS); 9.0 + 0.3 to 8.1 
7-3 
-6 
+ 0. 9 (NS). Tetrodotoxin 5 x 
-7 
10 M and 3 x 10 M did not elevate 
ventricular fibrillation threshold levels prior to coronary artery 
ligation. Tetrodotoxin 3 X l0-
6M but not 5 X completely 
prevented the fall in ventricular fibrillation threshold during the 
entire period of acute myocardial ischemia (Fig 7-2). Protection against 
ventricular fibrillation was associated with total coronary flow rates 
and heart rates similar to the control series subject to coronary artery 
ligation (Table 7-1). Ventricular antiarrhythmic activity was not 
accompanied by preservation of adenosine triphosphate, phosphocreatine or 
glycogen content in the ischemic myocardium (Table 7-2); moreover there 
was no reduction in the lactate or cyclic AMP content in the ischemic 
myocardium (Table 7-~). 
3. DISCUSSION 
[A) Fast channel blocking agents and ventricular antiarrhythmic 
activity 
Lignocaine 3 X 
-s -6 
10 M and tetrodotoxin 3 x 10 M each 
completely prevented the fall in the ventricular fibrillation threshold 
during acute regional myocardial ischemia. Cardinal and associates 
(1981) showed that lignocaine 2 X prevents spontaneous 
ventricular fibrillation in the ischemic porcine heart, whilst Borer et 
al (1976) illustrated that in concentrations of 5 X to 3 X 
lignocaine reduces the incidence of ischemic ventricular 
fibrillation in the dog. 
Protection against ventricular fibrillation was not due to 
reduction in heart rate or dependent on preservation of total coronary 
flow rate during acute myocardial ischemia. Moreover, ventricular 
antiarrhythmic activity was not the result of preservation of high energy 
phosphate stores in the ischemic myocardium, 
metabolic factor in the mechanism of protection. 
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thereby excluding a 
Lignocaine but not 
tetradotoxin decreased cyclic adenosine monophosphate content in the 
ischernic myocardium . Thus reduction in cyclic AMP content in the 
ischemic myocardium is not a prerequisite for protection against 
ventricular fibrillation. 
[BJ Transsarcolernrnal sodium, intracellular sodium and 
ventricular antiarrhythrnic activity 
Lignocaine reduces the transsarcolernrnal inward sodium current in 
cardiac muscle (Colatsky, 1982; Bean et al, 1981) and also decreases the 
intracellular sodium activity of sheep heart Purkinje fibres (Deitrner and 
Ellis, 1980; Eisner et al, 1983) • The latter action of lignocaine has 
been ascribed to reduction in transsarcolernrnal sodium influx which in 
turn allows the sodium potassium pump to extrude more sodium than that 
which leaks in; hence reduction in intracellular sodium activity 
occurs. Do these findings, therefore, indicate that the transsarcolernrnal 
sodium inward current plays a major role in ventricular arrhythrnogenesis 
during acute regional myocardial ischemia? A factor which questions this 
hypothesis is that lignocaine not only affects the fast sodium channel, 
but also produces an increase in the time independent outward potassium 
(}.-rr\S dr:,v f ll"'& t2>cj<j€r (q 72._) 
current;/ such an effect may account for ventricular antiarrhythrnic 
activity. Further investigation was, therefore, undertaken with 
tetrodotoxin, a specific inhibitor of the voltage dependent fast sodium 
channel (Blankenship, 1976; Coraboeuf and Vasort, 1968)). Tetrodotoxin 
3 x 10 -
6
M completely prevented the fall in the ventricular fibrillation 
threshold during acute myocardial ischemia. At approximately this 
concentration in sheep heart Purkinje fibres, tetrodotoxin inhibited the 
transsarcolemrnal · inward sodium current and reduced the intracellular 
- ·- - ' • - -~ - • -" - . - - ~ ~ ... - ~ ~, = .. - er" • • • • - - ' • 
- ~-~,a.....,..._....,_....,._-.,..-,.,,i;a.,,a,1,:lJioMA.IW',1•<1 
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sodium activity by 40% (Deitmer and Ellis, 1980). The findings with 
lignocaine and tetrodotoxin provide strong evidence that the 
transsarcolemmal sodium inward current plays a major role in the genesis 
of ventricular fibrillation. 
[C] Mechanism of ventricular antiarrhythmic action 
The antiarrhythmic action of lignocaine and tetrodotoxin is 
probably due to a decrease of the transsarcolemmal inward sodium current 
with reduction in the excitability of cardiac tissue. Such an effect 
would inhibit depressed fast responses and thereby prevent reentrant 
circuits critical to the genesis of ventricular fibrillation. 
Experimental evidence favouring this concept include the following: (1) 
Lazzara and associates (1978b) illustrated that lignocaine and 
tetrodotoxin abolished propagating depressed action potentials and 
extinguished very slow conduction of both ischemic and hypoxic canine 
ventricular myocardial fibres; ( 2) Kupersmith et al ( 1975) showed that 
lignocaine selectively depressed conduction in the ischemic myocardium; 
( 3) Ari ta and co-workers ( 1983) showed that lignocaine and tetrodotoxin 
decreased conduction velocity of depressed fast responses and produced 
complete conduction block and inexcitability of cardiac tissue; (4) 
Lignocaine and tetrodotoxin abolish depressed fast responses but do not 
alter slow response action potentials (Brennan et al, 1978). 
An alternative explanation for the antiarrhythmic action is 
inhibition of the arrhythmogenic transient non-specific inward current 
which predisposes to afterdepolarizations and triggered automaticity. 
Both lignocaine and tetrodotoxin, by decreasing the inward sodium 
current, reduce the intracellular sodium and thereby the intracellular 
calcium ion concentration; the latter effect inhibits the arrhythmogenic 
transient non-specific inward current. 
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Although the antiarrhythmic action of lignocaine and 
tetrodotoxin may be mediated by either one of the two above mechanisms, 
the critical .factor to both is inhibition of the transsarcolemmal sodium 
inward current. 
4. CONCLUSIONS 
1. Lignocaine and tetrodotoxin each completely prevented the fall in the 
ventricular fibrillation threshold during acute myocardial ischemia. 
2. Protection was not due to reduction in heart rate, coronary artery 
vasodilation, preservation of energy status or reduction in myocardial 
cyclic adenosine monophosphate. -
3. Ventricular antiarrhythmic activity appears to be due to inhibition 











EFFECT OF LIGNOCAINE ON VENTRICULAR FIBRILLATION
 
THRESHOLD DURING ACUTE REGIONAL MYOCARDIAL ISCHE
MIA 
- Control _5 
- - Lignocaine 5 x 10 M -5 
•••••••· Lignocaine 3 x 10 M 
- L ignocaine 1 x 10-
5M 
* p< 0·01 
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EFFECT OF TETRODOTOXIN ON VENTRICULAR FIBRILLATION 





- - Tetrodotoxin 3 x 10- M 
o-- Tetrodotoxin 5 x 10-7 M 
* p< 0·05 **P<0,01 T 






2 5 10 15 
Minutes after coronary artery ligation 
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Table 7-1 Effect of fast channel blocking agents on heart rate, 
total coronary flow rate and ventricular 
fibrillation threshold after coronary artery ligation 
Procedure 
1. Non-ligated heart 
2. Coronary artery 
ligation (CAL) 
p vs 1 
3. CAL+ lignocaine 
10-6M 
p vs 1 
p vs 2 
4. CAL+ lignocaine 
5 x 10-5M 
p vs 1 
p vs 2 
5. CAL+ tetrodotoxin 
5 X 10-7M 
p vs 1 
p vs 2 
6. CAL+ tetrodotoxin 
3 X l0-6M 
p VS 1 
p vs 2 
Number of hearts= 5-12 
Values represent Mean+ SEM 
Mean total 
Mean heart rate coronary flow VFT 15' CAL 
(beats/min) (mls/min) (rnA) 
243 + 10 7.8 + 0.5 10.0 + 0.3 
199 + 14 3.9 + 0.5 2.0 + 0.3 
<0.02 < 0. 01 < 0. 01 
172 + 5 3.9 + 0.3 2.8 + 0.4 
<0.01 <0. 01 <0.01 
NS NS NS 
207 + 8 4.9 + 0.3 13.0 + 1.0 
<0.05 < 0. 05 NS 
NS NS < 0. 01 
199 + 4 4.0 + 0.3 3.0 + 0.4 
<0.01 <0. 01 < 0. 01 
NS NS NS 
200 + 10 4.3 + 0.4 12.7+1.5 
<0.02 <0. 01 NS 
NS NS < 0.01 
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Table 7-2 Effect of fast channel blocking agents on tissue 
metabolic status 15 minutes after coronary artery 
ligation 
Ischernic myocardium 
ATP PCr Glycogen Lactate 
pmol/g fresh wt 
1. Coronary artery ligation 2.07 1.54 2.54 16.41 
(CAL) (n=12) +0.23 +0.21 +0.67 +2.33 
2. CAL + tetrodotoxin 0.78 0.90 2.48 15.11 
3 x 10-6M (n=S) +0.10 +0.14 +0.29 +2.14 
p vs 1 < 0. 01 NS NS NS 
3. CAL + lignocaine 0.62 0 .HO 11.49 
3 X 10-SM (n=S) +0.17 +0.12 +0.86 
p vs 1 <0.01 < 0. 01 NS 






p vs 1 
CAL + lignocaine 
3 x 10-5M 
p vs 1 
p vs 2 
CAL + lignocaine 
5 x 10-5M 
p vs 1 
p vs 2 
CAL + tetrodotoxin 
3 x 10-6M 
p vs 1 
p vs 2 
Effect of fast channel blocking agents on tissue 
cyclic AMP and ventricular fibrillation threshold 




(nrnol/g fresh wt) 
0.44 + 0.02 
0.54 + 0.02 0.71 + 0.03 
< 0. 01 < 0.001 
0.33 + 0.02 0.50 + 0.02 
< 0. 01 NS 
< 0.001 <0.01 
0.34 + 0.02 0.45 + 0.02 
<0.01 NS 
<0.001 <0. 01 
0.54 + 0.03 0.63 + 0.03 
<0. 02 <0.001 
NS NS 
Number of hearts= 5-12 
Values represent Mean+ SEM 
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VFT 15' CAL 
(rnA) 
10.0 + 0.3 
2.0 + 0.3 
< 0.01 
11.8 + 1.8 
NS 
< 0. 01 
13.0 + 1.0 
NS 
< 0. 01 
12.7+1.5 
NS 
< 0. 01 
CHAPTER 8 
CONCLUSIONS 
[A ) VENTRICULAR FIBRILLATION INDUCED BY ENHANCED ADRENERGIC 
STIMULATION IN THE NON-ISCHEMIC HEART 
8-1 
(1) Beta-adrenoceptor antagonist agents, in concentrations 
producing beta-receptor antagonism, prevent the adrenaline-induced 
vulnerabiliity to ventricular fibrillation. The beta-adrenergic receptor 
is directly implicated i n the genesis of ventricula r fibrillation induced 
by enhanced adrenerg ic stimulation. Cy cl i c AMP, the proposed 
intracellular second messenger of beta-receptor stimulation may not 
mediate the arrhythmogenic effect of enhanced adrenergic activity, but 
simply be an epi-phenomenon. 
(2 ) Calcium antagonist procedures prevent the adrenaline-induced 
vulnerability to ventricular fibrillation. Calcium ions appear to act as 
the intracellular second messenger in mediating the arrhythmogenic effect 
of enhanced adrenergic stimulation. 
[BJ VENTRICULAR FIBRILLATION INDUCED BY ACUTE REGIONAL MYOCARDIAL 
ISCHEMIA 
(1) Beta-adrenoceptor antagonist agents, in concentrations 
producing beta-receptor antagonism, are ineffective in preventing the 
enhanced vulnerability to ventricular fibrillation. In concentrations 
higher than that required to produce beta-adrenoceptor antagonism, some 
but not all beta-antagonist agents prevent the enhanced vulnerability to 
8-2 
ventricular fibrillation. The beta -adrenergic receptor does not appear 
to play a role in the genesis of ventricular fibrillation during acute 
myocardial ischemia. The ventricular antiarrhythmic activity of some 
beta-adrenoceptor antagonist agents appears to be due to a non-specific 
effect, eg. 'membrane stabilizing activity'. 
(2) The accumulation of cyclic AMP in the ischemic myocardium 
appears to be dependent on factors other than beta-receptor stimulation. 
Cyclic AMP may be linked to ventricular fibrillation but only in certain 






adrenoceptor antagonist agents prevent 
the enhanced vulnerability to ventricular fibrillation. The ventricular 
antiarrhythmic activity appears to be due to a non-specific effect, i.e. 
'membrane stabilizing activity' or prolongation of action potential 








receptor in ventricular arrhythmogenesis, the anatomical 
distribution of myocardial alpha1 
and alpha
2 
adrenoceptors and their 
regulation of extracellular and intracellular calcium ion movement needs 
to be clearly defined. 
(4) Calcium channel antagonist agents and a reduction in 
extracellular calcium concentration attenuated the enhanced vulnerability 
to ventricular fibrillation. The transsarcolemmal calcium current 
appears to play a role in the genesis .of ventricular fibrillation. 
( 5) Fast channel blocking agents prevented the enhanced 
vulnerability to ventricular fibrillation. The transsarcolemmal sodium 
current appears to play a major role in the genesis of ventricular 
fibrillation. 
[C] POSSIBLE ELECTROPHYSIOLOGICAL MECHANISM OF VENTRICULAR 
FIBRILLATION DURING ACUTE REGIONAL MYOCARDIAL ISCHEMIA 
8-3 
This thesis does not address the electrophysiological mechanism of 
ventricular fibrillation, hence an answer to this question is not 
evident. Nevertheless, based on the findings that the transsarcolernrnal 
calcium and sodium ionic currents both appear to play a role in the 
genesis of ventricular fibrillation, inferences as to the possible 
electrophysiological mechanism of ventricular fibrillation can be drawn. 
(1) A likely inference is that slow response action potentials and 
depressed fast response action potentials may both co-exist in the 
ischernic myocardium and each may predispose to ventricular fibrillation. 
Is there any evidence to support this hypothesis? Calcium channel 
antagonist agents suppress depressed action potentials and automatici ty 
in some fibres whereas fast channel blocking agents suppress depressed 
action potentials and automatici ty in other fibres of diseased human 
ventricular myocardium, resected for control of malignant ventricular 
arrhythmias. Both slow responses and depressed fast responses have been 
proposed to participate in abnormal impulse generation and propagation 
and to modulate ventricular arrhythmias in diseased human ventricular 
myocardium (Gilmour et al, 1983). 
(2) Inhibition of the transsarcolernrnal calcium current decreases 
intracellular calcium concentration, whereas inhibition of the 
transsarcolernrnal sodium current decreases intracellular sodium and 
thereby the intracellular calci urn concentration. The ventricular 
antiarrhythrnic effect of both calcium antagonist procedures and fast 
channel blocking agents may therefore be explicable on the basis of 
reduction in cytosolic calcium concentration. Cytosolic calcium overload 
(which occurs during acute myocardial ischemia) predisposes to 
8-4 
afterdepolarizations and may thereby induce triggered automatici ty and 
ventricular arrhythmias. Afterdepolarization induced triggered 
automaticity is therefore an alternative electrophysiological mechanism 
of ventricular fibrillation. 
Future investigation should therefore evaluate: 
(i) the exact nature of the electrophysiological alterat~on which 
evokes ventricular fibrillation, i.e. slow response action potential, 
depressed fast response action potential or afterdepolarization, and 
(ii) define the role of intracellular sodium ions and calcium ions 
in the genesis of ventricular fibrillation. 
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